{"Title": ["First Week of February 2021 Options Trading For bluebird bio (BLUE)", "Analysts Expect 10% Gains Ahead For BBH", "Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics", "bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene Therapy", "Better Buy: bluebird bio vs. Gilead Sciences", "FDA Mishaps Have Investors Asking \u201cWhat\u2019s Going On With bluebird bio?\u201d", "BUZZ-U.S. STOCKS ON THE MOVE-Dynavax Technologies, Arbutus Biopharama, Flotek", "Health Care Sector Update for 05/18/2020: JNJ,VIR,ARNA,BLUE", "First Week of February 2021 Options Trading For bluebird bio (BLUE)", "BUZZ-U.S. STOCKS ON THE MOVE-Centric Brands, Fulgent Genetics, Moderna", "Legend Biotech Makes Plans to IPO With Backing From Johnson & Johnson", "BUZZ-U.S. STOCKS ON THE MOVE-Akers Biosciences, Comstock, Virtusa", "FDA Snubs BMY And BLUE, Stocks That Moved On ASCO Abstracts (ARVN, CTMX, MGNX)", "BUZZ-U.S. STOCKS ON THE MOVE-Cornerstone Building, Aerpio Pharma, J.C. Penney", "Better Buy: bluebird bio vs. Exelixis", "Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline", "Health Care Sector Update for 05/18/2020: VIR,ARNA,BLUE", "BUZZ-U.S. STOCKS ON THE MOVE-Aerpio Pharma, J.C. Penney, bluebird bio", "U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma", "U.S. FDA decides to not review Bristol Myers, bluebird therapy for multiple myeloma", "Health Care Sector Update for 05/11/2020: PLX,APOP,ZYNE,BLUE", "Health Care Sector Update for 05/11/2020: APOP, ZYNE, BLUE, BMY", "Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout", "Bristol Myers to pay bluebird $200 mln for future royalties on cancer therapies", "BUZZ-U.S. STOCKS ON THE MOVE-Aerpio Pharma, J.C. Penney, Genocea Bio", "Better Buy: Crispr Therapeutics vs. bluebird bio", "How These 15 Stock Suggestions Fared Against the Market", "Why bluebird bio Stock Soared Today", "bluebird bio is Now Oversold (BLUE)", "So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature", "Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday", "Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday", "Bristol Myers to pay $200 mln to Bluebird for royalty obligations", "Hematology-Focused Biotech Imara to IPO Soon", "Is bluebird bio a Millionaire-Making Biotech?", "Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease", "3 Cancer Treatment Stocks to Buy Right Now", "Health Care Sector Update for 02/19/2020: CLRB,HQY,CTSO,BLUE", "Noteworthy Wednesday Option Activity: UNH, HQY, BLUE", "Health Care Sector Update for 02/19/2020: HQY,CTSO,BLUE", "Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking Today", "Why bluebird bio's Q4 Results Really Don't Matter", "bluebird bio Beats Its Q4 Revenue Target but Misses on EPS", "3 Best Biotech Stocks to Buy for the Next Decade", "Analysts Predict 19% Upside For FBT", "Better Buy: bluebird bio vs. Gilead Sciences", "Bristol-Myers Squibb Stock Is Too Cheap to Ignore", "First Week of March 20th Options Trading For bluebird bio (BLUE)", "Stock Alert: Bluebird Bio Stock Down 8% On Mixed Q4 Results", "Analysts Forecast 14% Gains Ahead For The Holdings of BBH", "3 Beaten-Up Biotech Stocks That Just Got More Enticing", "Thursday's ETF Movers: CQQQ, FBT", "The Top Biotech Stocks to Watch Following ASH 2019", "Noteworthy Wednesday Option Activity: ATH, WMB, BLUE", "Here\u2019s Why bluebird bio Shares Jumped Almost 12% Today", "FDA Puts GlaxoSmithKline's Blood Cancer Drug In the Fast Lane", "5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now?", "CRISPR vs. Gene Therapy Round 1: What Investors Need to Know", "Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed", "Is bluebird bio a Buy?", "The Implied Analyst 12-Month Target For OSIZ", "Health Care Sector Update for 11/01/2019: BGNE,AMGN,AMED,BLUE", "Health Care Sector Update for 11/01/2019: BGNE,AMGN,AMED,BLUE", "BGNE Soars, DRNA Hits New High On Roche Deal, FDA Heeds REPH's Request", "3 Reasons CRISPR Therapeutics Stock Can Reach Record Highs Again", "Why Did the Market Whack This IPO?", "3 Cancer-Fighting Drug Stocks to Buy Right Now", "Monday's ETF with Unusual Volume: IWB", "Week Ahead In Pharmaceuticals: 7 Stocks To Watch (AIMT, LXRX, TXG\u2026)", "Here's Why bluebird bio Fell 21.3% in August", "bluebird bio Enters Oversold Territory", "Health Care Sector Update for 08/22/2019: BLUE,CNMD,NTRA,RTRX", "Health Care Sector Update for 08/12/2019: SOLY,MLND,ORGS,BLUE", "Health Care Sector Update for 08/12/2019: MLND,ORGS,BLUE", "bluebird bio Prepares for Launch", "Oversold Conditions For bluebird bio (BLUE)", "IYH's Underlying Holdings Imply 14% Gain Potential", "Tuesday's ETF Movers: FBT, XME", "Is bluebird bio a Buy?", "First Week of BLUE February 2020 Options Trading", "Where Will bluebird bio Be in 1 Year?", "What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?", "Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?", "Notable Monday Option Activity: PSMT, ANET, BLUE", "Health Care Sector Update for 06/10/2019: BLUE,TLRY,ONCE", "Top 5 Stocks in the Fight Against Cancer", "It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy", "11 Biotech Stocks to Put on Your Radar Soon", "Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big", "Health Care Sector Update for 05/16/2019: BLUE,MRTX,AGIO,EDAP,AMGN", "5 Biotech Stocks for a Long-Lived Portfolio", "Health Care Sector Update for 06/10/2019: RWLK,TLRY,BLUE,ONCE", "20 High-Growth Stocks For The Next 20 Years", "How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life", "This Is Why You Shouldn\u2019t Count Regeneron Stock Out", "Top Gene-Sequencing Stocks for 2019", "Here's Why Shares of bluebird bio Slumped Today", "BLUE Makes Notable Cross Below Critical Moving Average", "BLUE Makes Notable Cross Below Critical Moving Average", "Analysts Expect 14% Gains Ahead For The Holdings of RXL", "20 High-Growth Stocks For The Next 20 Years", "How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life", "Commit To Purchase bluebird bio At $105, Earn 13.3% Using Options", "2 Blockbuster Gene Therapy Programs to Watch in 2019", "IWF's Underlying Holdings Imply 10% Gain Potential", "Celgene (CELG) Submits NDA for MS Drug to FDA for Review", "Why bluebird bio Could Deliver Miracles to Genetic Disease Patients", "Celgene (CELG) Submits Application for MS Drug in Europe", "Here's Why bluebird bio Gained 16.3% in February", "With a Stocked War Chest, bluebird bio Presses On", "bluebird bio Breaks Above 200-Day Moving Average - Bullish for BLUE", "Better Buy: bluebird bio vs. Gilead Sciences", "bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y", "Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates", "Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?", "Celgene (CELG) Submits Application for MS Drug in Europe", "Here's Why bluebird bio Gained 16.3% in February", "With a Stocked War Chest, bluebird bio Presses On", "bluebird bio Breaks Above 200-Day Moving Average - Bullish for BLUE", "Better Buy: bluebird bio vs. Gilead Sciences", "bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y", "Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates", "Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline", "Health Care Sector Update for 01/23/2019: BLUE,CNMD,ATHX,BLPH", "Here's Why CRISPR Therapeutics Stock Fell Today", "Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?", "Here's What Pushed bluebird bio Stock Down 44.3% in 2018", "3 Biotech Stocks to Watch in 2019", "Notable Friday Option Activity: X, C, BLUE", "Celgene (CELG) Provides Guidance for 2019, Updates Pipeline", "5 Best Biotech Bets Likely to Outperform Estimates in Q4", "Here's Why bluebird bio Shares Got Knocked Down 19.3% in December", "Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout", "Here\u2019s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene", "Bristol-Myers bulks up with $74 bln deal to buy Celgene", "bluebird bio Enters Oversold Territory (BLUE)", "Forget bluebird bio, Amgen Is a Better Biotech Stock", "2 Sets of Disasters Biotech Will Pay For in 2019", "Here's Why CRISPR Therapeutics Tanked 25.5% in December", "Why CRSP Stock Has Added Layers of Risk", "Dow Drops 352 Points Because This Is Way More Than a Trade War", "Can Celgene and bluebird bio Survive a Two-Pronged Attack?", "Global Blood Therapeutics' Voxelotor on Faster Approval Path", "Celgene (CELG) Announces Various Cancer Data at ASH 2018", "Top Biotech Stocks to Watch at ASH 2018", "Notable Friday Option Activity: BLUE, AZO, RMTI", "Notable Friday Option Activity: BLUE, MYL, BEL", "Celgene & Bluebird's CAR T Therapy Study Completes Enrollment", "My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy", "The Implied Analyst 12-Month Target For IWP", "Waiting for bluebird bio to Sing at ASH", "Here's Why bluebird bio Fell 21.4% in October", "3 Cancer Stocks to Watch in December", "3 Top Biotech Stocks to Buy in November", "Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News", "Celgene & Bluebird's CAR T Therapy Study Completes Enrollment", "Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates", "Here's Why bluebird bio Jumped 13.5% Today", "Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View", "Here's Why bluebird bio Dropped 13.3% in September", "Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study", "Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy", "Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line", "Micron Slumps, AT&T Rises as Dow Targets Another New High", "December 21st Options Now Available For bluebird bio (BLUE)", "Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory", "Bluebird Bio Stock May Have Upside of at Least 60 Percent", "Notable Monday Option Activity: BLUE, MCFT, SFLY", "Is Now a Good Time to Buy Celgene?", "Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete -- Here's Why That's Great for Investors", "First Week of May 2019 Options Trading For bluebird bio (BLUE)", "bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy", "3 Hot Biotech Stocks Set to Explode", "Noteworthy Friday Option Activity: PANW, BBY, BLUE", "Software and Biotech Are Eating the World", "O Canada...We're Waiting On You", "3 Top Healthcare Stocks to Buy Right Now", "Play The Future of Gene Therapy With These 5 Biotech Stocks", "Upcoming Earnings to Watch: KR, PLAY, TLRD", "Turkey Ruins Week for Dow, S&P", "Carl Icahn Fires Shots at Express Scripts", "Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges", "Bluebird Bio Stock Is for Long-Term Investors Only", "Why Is Bluebird Bio (BLUE) Stock Gaining Today?", "Morning Movers: Intel Drops, Qualcomm Rises, Bluebird Flies", "Notable Monday Option Activity: TRU, BLUE, CVGI", "Is Celgene Set to See Improved Results in the Second Half?", "T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch", "bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss", "What's in Store for Celldex (CLDX) This Earnings Season?", "What's in the Cards for Humana (HUM) Stock in Q2 Earnings?", "Can Celgene\u2019s Most Important Drugs Keep Growing?", "Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View", "Did This Top Biotech Stock Just Go on Sale?", "bluebird bio Prepares Its \"Transition to a Commercial Company\"", "T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch", "Celgene Reports Positive Data on Tecentriq, Abraxane Study", "Financial Exchange Stock Talk: Joe McCann On Loxo Oncology And bluebird bio", "Surprising Analyst 12-Month Target For EQWM", "Celgene, Acceleron Report Positive Data on Thalassemia Drug", "Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?", "Here's Why bluebird bio, Inc. Is Down Today", "Better Buy: Gilead Sciences, Inc. vs. Celgene", "Celgene Investors Breathe a Sigh of Relief After Acceleron's Success", "IWN, UMPQ, BLUE, WTFC: ETF Inflow Alert", "Why Sangamo Therapeutics and bluebird bio Slipped Lower Today", "Notable Two Hundred Day Moving Average Cross - BLUE", "First Week of BLUE February 2019 Options Trading", "Morning Movers: As Dow Tumbles 360 Points, Bluebird Bio, Verizon Rise", "Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far", "The 2 Most Wildly Overvalued Biotech Stocks Right Now", "Celgene Investors Breathe a Sigh of Relief After Acceleron's Success", "IWN, UMPQ, BLUE, WTFC: ETF Inflow Alert", "Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst", "#ASCO18: A Weekend of Surprises", "Something Borrowed, Something Blue, Volume 2: It's Been a Roller-Coaster Ride for BLUE Shareholders", "iShares Russell 2000 ETF Experiences Big Outflow", "bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA", "Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio", "Interesting BLUE Put And Call Options For July 20th", "IWM, NKTR, GRUB, BLUE: Large Inflows Detected at ETF", "Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.", "3 Growth Stocks at Deep-Value Prices", "bluebird bio Looks for Data Ahead", "Something Old, Something New, Something Borrowed, Volume 2: A Particularly Motley Podcast", "bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA", "Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio", "Interesting BLUE Put And Call Options For July 20th", "IWM, NKTR, GRUB, BLUE: ETF Outflow Alert", "2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line", "Is bluebird bio One Step Closer to Its First Commercial Drug?", "IWM, BLUE, MKSI, CW: Large Inflows Detected at ETF", "IWM, NKTR, BLUE, GRUB: ETF Outflow Alert", "Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength", "How The Pieces Add Up: VXF Targets $123", "Relative Strength Alert For bluebird bio", "IWM, BLUE, CW, AZPN: Large Outflows Detected at ETF", "Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate", "Analysts Predict 12% Upside For The Holdings of FNY", "Noteworthy Tuesday Option Activity: BAC, BLUE, CMI", "Is bluebird bio, Inc. a Buy on the Dip?", "Better Buy: Celgene Corporation vs. Biogen Inc.", "This Is My Favorite Biotech Stock To Buy On Sale", "Vanguard Small-Cap Growth ETF Experiences Big Inflow", "Near a 3-Year Low, Is Celgene Stock a Buy?", "Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics", "Why Sarepta (SRPT) Jumped and We Sold", "Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno", "Noteworthy ETF Outflows: VBK, XPO, BLUE, CPRT", "Better Buy: Celgene Corporation vs. Biogen Inc.", "This Is My Favorite Biotech Stock To Buy On Sale", "Vanguard Small-Cap Growth ETF Experiences Big Inflow", "Near a 3-Year Low, Is Celgene Stock a Buy?", "Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics", "IWM, VIXM: Big ETF Outflows", "How Celgene Hopes to Cash In on CAR-T", "Healthcare Heroes That Aren't Done Yet", "Here's Why bluebird bio Soared 15% in January", "Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January", "3 Top Biotherapeutics Stocks to Buy Now", "iShares Russell 2000 ETF Experiences Big Outflow", "Can CRISPR And 3 Small Biotech Companies Cure 10,000 Diseases?", "Celgene Looking Good With Plans for More Growth", "First Week of March 16th Options Trading For bluebird bio (BLUE)", "iShares Russell 2000 ETF Experiences Big Inflow", "Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?", "Noteworthy Wednesday Option Activity: CVLT, NAV, BLUE", "Bluebird Up on Buyout Speculation After Celgene/Juno Deal", "Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion", "These 3 Stocks Have Doubled Investors' Money", "Analysts More Bullish On Celgene-Juno, But Sales Outlook Nags", "Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?", "Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid", "bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session", "Healthcare: Is Celgene Going to Buy Juno Therapeutics?", "Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense", "Why Juno Therapeutics Stock Is Soaring Today", "Is Celgene (CELG) Looking to Take Over Juno Therapeutics?", "Noteworthy ETF Inflows: IWM, NKTR, BLUE, SAGE", "Juno Therapeutics Stock Rockets On Report That Celgene Is In Buyout Talks", "Why bluebird bio Is Soaring 11.9% Today", "Up 188.7%, Is bluebird bio. Stock Still a Strong Buy?", "What bluebird bio Wants You to Know About Its Business", "Celgene Provides 2017 Preliminary Results & 2018 View", "IWM, AGND: Big ETF Outflows", "bluebird bio Reaches Analyst Target Price", "Here's How bluebird bio, Inc. Crushed It in 2017", "2018 Should Be Better for Celgene Corporation and CELG Stock", "Here's What Celgene's Management Just Said About Its Future", "4 Biotech Stocks That More Than Doubled This Year", "What to Expect From Celgene Corporation in 2018", "Notable ETF Inflow Detected - IWN, MTG, STL, BLUE", "Why Juno Therapeutics Stock Fell Last Week", "Celgene Stock Up Huge On Exciting CAR-T News", "Celgene Shareholders Excited by CAR-T News", "CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More", "Here's Where Things Went Wrong for Celgene Corporation in 2017", "IWM, ENOR: Big ETF Outflows", "Here's Why Everyone's So Excited About bluebird bio", "Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs", "5 Biotech Buyout Candidates for 2018", "This Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs", "Company News For Dec 12, 2017", "Bluebird's Shares Jump on Strong Data for CAR-T Therapy", "ASH 2017 Recap: These Were the Big Winners and Losers", "Apple Leads Nasdaq Stocks Up; Is This The Best Bitcoin ETF To Trade?", "Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today", "Noteworthy Monday Option Activity: SBGI, BLUE, ONCE", "Biotech Stocks Soar On Trial Data At Hematology Conference", "Mid-Morning Market Update: Markets Edge Higher; 3M To Sell Communication Markets Division For $900M", "Futures Trend Higher As Upbeat Jobs Report Continues to Fuel Gains", "bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results", "ASH 2017: CAR-T Wallops Blood Cancer", "Apple Leads Nasdaq Stocks Up; Is This The Best Bitcoin ETF To Trade?", "Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today", "Noteworthy Monday Option Activity: SBGI, BLUE, ONCE", "Biotech Stocks Soar On Trial Data At Hematology Conference", "Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher", "Health Care Sector Update for 12/11/2017: BPMC,BLUE,VTGN", "Why Biotech Stocks May Wait A While Before Feeling The Love", "Morning Movers: Bluebird Bio, Solar Stocks Soar; Paccar Falls", "Here's Why bluebird bio's Shares Soared 24% in November", "iShares Russell 2000 ETF Experiences Big Inflow", "3 Biotech Stocks to Buy in December", "Does Gilead's Kite Acquisition Offer A New Buying Opportunity?", "IWM, BLUE, NKTR, MKSI: Large Inflows Detected at ETF", "Apple Strong; Square Eyes 5th Up Week; 1 Reason Why Biotechs Aren't Dead Yet", "CAR-T Therapy Space 2017 Progress Report", "Gilead Sciences to Acquire Cell Design Labs for $567 Million", "IWM, BLUE, NKTR, MKSI: ETF Inflow Alert", "Celgene CAR-T Therapy Gets Breakthrough Therapy Designation", "A Rare Quarterly Appearance by bluebird bio Inc.'s Management", "3 Top Healthcare Stocks to Buy in November", "5 Irresistible Reasons to Buy Celgene Stock Right Now (Hint: 1 Is that It's Dirt Cheap)", "BLUE Crosses Above Average Analyst Target", "Notable ETF Outflow Detected - IWM, BLUE, CW, STL", "Juno Therapeutics Back With New Data - Slingshot Insights' Idea Of The Month", "Morning Movers: Valeant Climbs, Sears Sinks, Herbalife Drops", "3 Reasons It's Smart to Buy Celgene's Stock Now", "IWM, BLUE, MKSI, STL: Large Inflows Detected at ETF", "Here's Why bluebird bio Inc. Is Surging Again Today", "How Blood-Disease Data Sent These 2 Biotech Stocks Flying", "Noteworthy Wednesday Option Activity: VMW, PRTY, BLUE", "What Happened in the Stock Market Today", "3 Stocks to Buy for a Better Tomorrow", "2 Top Pharma Stocks on Sale This Week", "Why Earnings Season Could Be Great for bluebird bio (BLUE)", "Vanguard Health Care Fund Buys 6 New Stocks in the 3rd Quarter", "Was Celgene\u2019s Third Quarter Really Crash-Worthy?", "Why Agenus Inc. Stock Briefly Popped Today", "Commit To Buy bluebird bio At $85, Earn 15.1% Using Options", "Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider", "Why bluebird bio Inc. Jumped Higher Today", "Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences", "Does Gilead Now Have A New Multi-Billion-Dollar Franchise?", "Buying And Selling Stocks Right Are Keys To This Top Mutual Fund's Success", "Celgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science?", "Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field", "IWM, BLUE, STL, AZPN: ETF Outflow Alert", "Why CRISPR Therapeutics AG Stock Lost Ground in September", "3 Gene Therapy Stocks That Could Make You Rich", "Why bluebird bio, Inc. Stock Gained 10% in September", "Here's Why Bluebird Bio (BLUE) Stock Is Falling Today", "IWM, RFAP: Big ETF Outflows", "Morning Movers: Sarepta Jumps, Bluebird Bio Drops, MGM Slumps", "Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing", "Morning Movers: Conn's Climbs, JB Hunt Soars, Goldcorp Gains", "Big Dose Of Healthy News Sends Biotech Stocks To New Heights", "Analysts Act on Health Care Stocks", "Why BlackBerry, AbbVie, and bluebird bio Jumped Today", "Bluebird Hits High On Bullish Report Highlighting Blood Drugs", "Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio", "3 Biotech Stocks With Major Catalysts in October", "IWM, ESGU: Big ETF Inflows", "Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?", "Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade", "Stock Indexes Mixed; Small Caps Lag", "5 Things You'll Want to Know From Celgene Corporation's Latest Presentation", "Here's What Lifted bluebird bio Inc. Stock 40% Higher in August", "IWM, KITE, GRUB, BLUE: Large Outflows Detected at ETF", "Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods", "5 Top Performing Stocks of the Top ETF of August", "bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session", "Thursday's ETF with Unusual Volume: BBH", "Don't Make This Huge Mistake With Celgene", "Health Care Sector Update for 08/31/2017: NVO,IPXL,STDY", "Wednesday's ETF Movers: BBH, GDXJ", "Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal", "Why bluebird bio Inc Jumped Higher Today", "Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap", "bluebird bio Reaches Analyst Target Price", "Here's What Else Gilead Sciences Gets by Buying Kite Pharma", "Why bluebird bio Inc Continued Its March Higher Again Today", "Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition", "Holding for Harvey", "Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today", "Is This Why bluebird bio Dipped 10.5% in July?", "bluebird bio Pauses During 2017 Data Blitz", "3 Reasons the Best Is Yet to Come for Celgene", "Celgene Corporation Continues to Get It Done", "Indecision Won't Kill You, But It Will Take Your Money", "A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared", "Novartis CAR-T Therapy Drug Recommended by FDA Panel", "A Junior Freak Out", "Billions of Dollars on the Line for Celgene With These 3 Small Biotechs", "IWM, BLUE, GPT, HLS: Large Outflows Detected at ETF", "How a Conference Caused Bluebird Bio's Shares to Rocket 33% in June", "ETF Winner of 1H17 and its Top 5 Stocks", "Commit To Buy bluebird bio At $50, Earn 10.4% Using Options", "Health Care Sector Update for 06/28/2017: BLUE,SPNC,CEMI", "3 Reasons to Buy Celgene Stock and Never Sell", "Why BlackBerry, Sysco, and bluebird bio Slumped Today", "3 Top-Performing Biotech Stocks This Week", "Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?", "Can Celgene Corporation Be a Value Stock?", "Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio", "2 Fastest Growing Biotech Stocks", "Health Care Sector Update for 06/28/2017: BLUE,SPNC,CEMI", "3 Reasons to Buy Celgene Stock and Never Sell", "Why BlackBerry, Sysco, and bluebird bio Slumped Today", "3 Top-Performing Biotech Stocks This Week", "Why bluebird bio Inc Flew Higher Today", "Notable Monday Option Activity: HAIN, URBN, BLUE", "What Investors Missed in the Market Last Week", "bluebird bio Reaches Analyst Target Price", "3 Promising Stocks to Buy Now", "Why bluebird bio Inc. Flew Higher Again Today", "Why Hawaiian Holdings, MBIA, and bluebird bio Jumped Today", "The First CAR-T Drugs Have Left the Gate", "BLUE Crosses Above Average Analyst Target", "bluebird bio Updates, Investors Wait", "4 Biotech Stocks Breaking Out On Positive Drug Developments", "Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals", "bluebird bio Inc Highlights a Data-Rich 2017", "These 4 Stocks Are Breaking Out", "Why bluebird bio Stock Surged 20.7% Higher in January", "3 Scorching Hot Biotech Stocks -- Are They Buys?", "Commit To Purchase bluebird bio At $45, Earn 22.2% Using Options", "Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.", "Better Buy: Intrexon Corporation vs. bluebird bio", "Better Buy: bluebird bio, Inc. vs. Kite Pharma", "Wednesday's ETF Movers: GDXJ, XBI", "Wednesday Sector Laggards: Drugs, Biotechnology Stocks", "Pre-Market Most Active for Dec 7, 2016 : TER, RAD, MT, PBR, BAC, VALE, MU, AAPL, TVIX, TLT, XIV, BLUE", "Why Flotek Industries, Oxford Industries, and bluebird bio Slumped Today", "Why bluebird bio Inc. Slipped Lower Today", "3 Small Biotech Stocks That Big Biotechs Like", "Why You Should Let Celgene Corporation Invest Your Money", "Why bluebird bio, Inc. Stock Is Soaring Today", "Stock Futures Flat Ahead of Manufacturing Data", "Pre-Market Most Active for Dec 1, 2016 : VALE, VCIT, CHK, WLL, TLN, PBR, VOD, SDRL, BLUE, BOJA, XIV, TVIX", "Why General Motors, bluebird bio, and Skechers USA Jumped Today", "A Potentially Astounding Advance in Multiple Myeloma", "Here's Why Bluebird Bio (BLUE) is Rallying Today", "Global Blood Therapeutics: Short-Sellers Could Be In For A Ride", "Better Buy: Juno Therapeutics vs. bluebird bio", "Why bluebird bio, Inc. Stock Got Crushed in October", "727.6 Million Reasons bluebird bio Inc. Has Time to Figure It Out", "Why bluebird bio Inc. Got Knocked Down Today", "3 Top Biotech Stocks to Buy in November", "Notable Two Hundred Day Moving Average Cross - BLUE", "Global Blood Therapeutics: Incredible Value At This Price", "Why Juno Therapeutics Inc Plummeted Today", "Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.", "Commit To Purchase bluebird bio At $30, Earn 14% Using Options", "Why Shares of bluebird bio Inc Took a Dive Today", "Health Care Sector Update for 10/14/2016: BLUE,ENZ,EGLT", "Friday's ETF Movers: IGV, XBI", "Friday Sector Laggards: Drugs, Biotechnology Stocks", "Better Buy: bluebird bio vs. Inovio Pharmaceuticals", "Why Global Blood Therapeutics Inc.'s Shares Are Soaring Today", "Peek Under The Hood: IYY Has 10% Upside", "XBI, SRPT, IONS, BLUE: ETF Inflow Alert", "XBI, SRPT, BLUE, IONS: ETF Inflow Alert", "Health Care Sector Update for 09/22/2016: AAAP,AVXL,BLUE", "Health Care Sector Update for 09/22/2016: LGND,AVXL,BLUE", "bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher", "XBI, IONS, MDVN, BLUE: ETF Inflow Alert", "Why bluebird bio, Inc. Stock Soared 37.4% in September", "Peek Under The Hood: IYY Has 10% Upside", "XBI, SRPT, IONS, BLUE: ETF Inflow Alert", "XBI, SRPT, BLUE, IONS: ETF Inflow Alert", "Health Care Sector Update for 09/22/2016: AAAP,AVXL,BLUE", "3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August", "bluebird bio Stock Up on Start of Phase III LentiGlobin Study", "3 Stocks to Watch Thursday: Viacom, Inc. (VIAB), Aerie Pharmaceuticals Inc (AERI) and Bluebird Bio Inc (BLUE)", "Why Cirrus Logic, bluebird bio, and GoPro Jumped Today", "XBI, IONS, SRPT, BLUE: ETF Outflow Alert", "XBI, IONS, SRPT, BLUE: ETF Inflow Alert", "bluebird bio Inc. Earnings: Waiting for Data", "Health Care Sector Update for 08/08/2016: PTI,MEIP,CHEK", "bluebird bio Inc. Tumbles 9.4% After Reporting a Wider-Than-Expected Q2 Loss", "3 Biotech Stocks to Buy on Sale", "We Did The Math BBH Can Go To $136", "Notable Two Hundred Day Moving Average Cross - BLUE", "XBI, IONS, SRPT, BLUE: ETF Outflow Alert", "Celgene (CELG), Jounce Strike Immunotherapy Collaboration", "This Could Be the Next Big Pharma Buyout", "Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold", "Why is Juno Therapeutics (JUNO) Stock Plunging 31% Today?", "5 Reasons bluebird bio Inc. Took Flight Today", "141 Reasons to Love Biotech Stocks", "Here's Why bluebird bio's Shares Dropped 10% on Monday", "Better Buy: Agenus Inc. vs. bluebird bio", "Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today", "Better Buy: bluebird bio vs. Inovio Pharmaceuticals", "Better Buy: Juno Therapeutics vs. bluebird bio", "Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys", "Juno (JUNO) Suffers Setback, Pivotal Study on Clinical Hold", "Health Care Sector Update for 04/20/2016: ONCS,OCLS,BLUE", "Health Care Sector Update for 04/20/2016: HNSN,OCLS,BLUE", "Commit To Buy bluebird bio At $35, Earn 22.1% Annualized Using Options", "Here's Why bluebird bio.'s Stock Tumbled in March", "Why bluebird bio's Stock Jumped 12.9% on Wednesday", "Anavex Life Sciences Stock: 1 Key Number You Must Know", "Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals", "bluebird bio, Inc. Takes Flight Towards First Approval", "Health Care Sector Update for 04/20/2016: ONCS,OCLS,BLUE", "Health Care Sector Update for 04/20/2016: HNSN,OCLS,BLUE", "Commit To Buy bluebird bio At $35, Earn 22.1% Annualized Using Options", "bluebird bio Inc.: Waiting for ASH", "Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today", "Why bluebird bio Inc.'s Stock Dropped 34% in January", "This Could Be the Next Big Pharma Buyout", "bluebird bio Inc. Takes Flight", "The Best Healthcare Stocks for 2016", "Kite Pharma Signs Deal with Leiden University Medical Center", "Why Bluebird Bio Inc.'s Stock Bounced Back", "Weakness Seen in bluebird (BLUE) : Stock PLunges 19.5%", "Oversold Conditions For bluebird bio (BLUE)", "Why bluebird bio Inc's Stock Is Tanking Today", "4 Top-Ranked Biotech Stocks on Sale", "Here's Why Bluebird Bio Turned in a Disappointing 2015", "Here's Why uniQure N.V.'s Stock Spiked Today", "bluebird bio Inc: Gene Therapy Is (Still) Hard", "Bear of the Day: Conn's (CONN)", "Clinical Data Whipsaws bluebird bio Inc. in November", "Thursday 12/10 Insider Buying Report: BLUE, LOB", "Bluebird Bio CEO Buys More Than 9,000 Shares", "Monday's ETF Movers: XLP, XBI", "Here's Why Bluebird Bio Turned in a Disappointing 2015", "Bluebird Bio Crashes After Clinical Trial Update", "Bluebird Bio Breaks Down Over Disappointing Clinical Update", "Pre-Market Most Active for Dec 7, 2015 : GMCR, SAN, BLUE, PBR, KMI, TVIX, FCAU, SDRL, GBT, XIV, AA, AAPL", "Health Care Sector Update for 12/07/2015: BLUE,XBIT,THLD", "Notable Monday Option Activity: BLUE, ENVA, CLR", "Why Global Blood Therapeutics Inc Shares Are Tanking Today", "What's Next for bluebird bio?", "Why Staples, Office Depot, and Bluebird Bio Slumped on Monday", "Kite Pharma (KITE) Posts Narrower Than Expected Loss in 3Q", "Kite (KITE) to Report 3Q Earnings: What's in Store?", "bluebird bio: ASH Puts a Damper on Earnings", "Here's Why bluebird bio Inc Crash Landed Today", "Pre-Market Most Active for Nov 5, 2015 : AWAY, FB, FEYE, BLUE, NVO, AAPL, EXPE, BAC, VALE, PBR, BP, ITUB", "Why bluebird bio Inc Is Flying Higher", "2 Biotech Stocks to Watch in December", "Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again", "3 Biotech Stocks That Have Been Unfairly Beaten Down", "Weakness Seen in bluebird (BLUE): Stock Tumbles 13.3%", "Interesting BLUE Put And Call Options For October 16th", "5 Sell-Ranked Biotechs That Fell More Than 5% Today", "Why bluebird bio Inc Shares Slumped Again", "bluebird bio (BLUE) Shares Cross Below 200 DMA", "5 High-Risk, High-Reward Stocks We're Watching", "Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again", "3 Biotech Stocks That Could Be Buyout Targets", "bluebird bio (BLUE) Shares Cross Below 200 DMA", "What Falling Estimates & Price Mean for bluebird bio (BLUE)", "Kite Pharma 2Q Loss Wider Than Expected, Pipeline in Focus - Analyst Blog", "Why Bluebird Bio Shares Dropped Today", "Did Hillary Clinton Cause bluebird bio to Slump Today?", "RSI Alert: bluebird bio (BLUE) Now Oversold", "Will Kite Pharma (KITE) Miss Earnings Estimates Yet Again? - Analyst Blog", "bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "What's in bluebird bio's Pipeline That Has Investors So Excited?", "Why Shares in Bluebird Bio Slumped By More Than 10% in June", "Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog", "Why Bluebird Bio Is Falling Today", "bluebird bio Reports Encouraging Data on Thalassemia Drug - Analyst Blog", "The Unique Case For Small Cap ETFs", "Stocks To Watch in Orphan Drugs", "Health Care Sector Update for 06/09/2015: CBMG,BLUE,SAGE,IRWD", "3 Surprising Biotech Stocks That Are Surging Higher", "Notable ETF Outflow Detected - IWO, ISIS, DXCM, BLUE", "bluebird Amends Collaboration Agreement with Celgene - Analyst Blog", "Kite Pharma and Bluebird Tie Up for HPV Cancer Targets - Analyst Blog", "Investing for Beginners: How to Start in Biotech", "Five Prime Therapeutics (FPRX) Jumps: Stock Rises 15.1% - Tale of the Tape", "Futures Gain Traction on Bargain-Hunting, Buoyed by Tiffany's Earnings", "Midday Update: Stocks Recover as Europe Swings Higher, Investors Shop for Bargains", "Uh-Oh! Billionaire George Soros Just Stepped on Another Biotech Landmine", "The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases", "Why Shares in Bluebird bio, Inc. Are Soaring", "Bluebird bio Larger Than S&P 500 Component Allegion plc", "bluebird bio Plans to Sing in June", "Zacks Investment Ideas feature highlights: Celladon, Novavax and Bluebird Bio - Press Releases", "Biotech Bubble Bursting? 3 Stocks I Want to Buy", "Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?", "Why uniQure N.V. Stock Skyrocketed Today", "3 Events That Could Sink the Biotech Sector This Year", "1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire", "bluebird bio (BLUE) Shows Strength: Stock Rises 9.2% - Tale of the Tape", "Use Options For a Chance To Buy BLUE at a 52% Discount", "Could This Clinical-Stage Biotech Stock Soar in April?", "Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia", "Use Options For a Chance To Buy BLUE at a 56% Discount", "Ecolab's (ECL) Q4 Earnings: Will it Disappoint Estimates? - Analyst Blog", "Will LabCorp (LH) Surprise Earnings Estimates this Season? - Analyst Blog", "Will DENTSPLY International (XRAY) Miss Earnings in Q4? - Analyst Blog", "Could These Experimental Drugs Eclipse Harvoni's Historic Launch?", "What's in Store for Acadia Healthcare (ACHC) this Earnings? - Analyst Blog", "bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: Jan. 25-31, 2015", "Use Options For a Chance To Buy BLUE at a 31% Discount", "5 Cant-Miss Reasons Why Celgene Corporation Could Soar", "State of the Union Address Investing Idea: Precision Medicine", "First Week of BLUE August 21st Options Trading", "Will Masimo Corp (MASI) Disappoint Q4 Earnings Estimates? - Analyst Blog", "3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015", "These 3 Biotech Stocks Tripled Investors' Money in 2014", "Growth Stocks 2015: 3 Companies With Room to Run", "How These 3 Stocks Doubled Investors' Money in Q4", "The Market's Top 10 Stocks of 2014", "Insiders Were Right: bluebird bio Makes New 52-Week High", "Use Options For a Chance To Buy bluebird bio at a 34% Discount", "Is Celgene Corporation a Takeover Target in 2015?", "3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015", "3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015", "Twitter's Favorite Biotech and Pharma Stocks", "bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog", "A Biotech Company With One Of The Normal Risks Reduced", "US Stocks Seen Extending Losses in Tune With World Markets on Growth Concerns; Weak Oil Futures", "bluebird bio (BLUE) in Focus: Stock Surges 9.4% - Tale of the Tape", "Notable ETF Outflow Detected - XBI, AGIO, BLUE, RCPT", "Use Options For a Chance To Buy bluebird bio at a 39% Discount", "Can the Uptrend Continue for Bluebird (BLUE)? - Tale of the Tape", "Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog", "Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog", "Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog", "bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape", "bluebird bio director buys close to 3,000 shares", "US Futures Extend Losses as Oil Prices, China Weigh on Global Sentiment", "Sector Update: Healthcare", "Commit To Buy bluebird bio At $30, Earn 44.2% Annualized Using Options", "Sector Update: Healthcare Stocks Tumble; bluebird bio Clipped After Disclosing Plans to Sell $100 Mln of Its Shares", "Friday's ETF Movers: IBB, GDXJ", "Bluebird (BLUE) Enters Overbought Territory - Tale of the Tape", "Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape", "Sector Update: Health Care", "bluebird bio (BLUE) Enters Overbought Territory - Tale of the Tape", "bluebird bio (BLUE) Jumps: Stock Adds 27.3% in Session - Tale of the Tape", "Zacks Rank #5 Additions for Thursday - Tale of the Tape", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Zacks Rank #5 Additions for Wednesday - Tale of the Tape", "bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape", "After Hours Most Active for Feb 7, 2014 : BAC, JNPR, ETE, WMB, BHI, JPM, TTWO, QQQ, WEN, MSFT, BLUE, INTC", "Pre-Market Most Active for Jun 16, 2014 : MDT, COV, FIO, NOK, WMB, BLUE, TWTC, WFT, YHOO, AAXJ, ACHN, AAPL", "Sector Update: Healthcare", "New Stock Coverage: Time to Put Your Nest Egg in Twitter?", "US IPO Recap: Biotech success continues, but three deals delayed or postponed", "bluebird bio prices upsized IPO above the range at $17", "6 US IPOs planned for the week of Jun 17", "Gene therapy biotech bluebird bio sets terms for $75 million IPO", "Gene therapy biotech bluebird bio files for a $86 million IPO", "Sector Update: Healthcare Shares Flat in Pre-Market; Oramed Drops 16% on Share Offering"], "Elapsed Time": ["JUN 19, 2020", "JUN 18, 2020", "JUN 14, 2020", "JUN 12, 2020", "JUN 11, 2020", "MAY 22, 2020", "MAY 19, 2020", "MAY 18, 2020", "JUN 19, 2020", "MAY 18, 2020", "MAY 14, 2020", "MAY 14, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 18, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 13, 2020", "APR 30, 2020", "APR 28, 2020", "APR 9, 2020", "APR 1, 2020", "APR 1, 2020", "MAR 16, 2020", "MAR 15, 2020", "MAY 11, 2020", "MAR 5, 2020", "MAR 4, 2020", "FEB 23, 2020", "FEB 23, 2020", "FEB 19, 2020", "FEB 19, 2020", "FEB 19, 2020", "MAR 12, 2020", "FEB 19, 2020", "FEB 18, 2020", "FEB 16, 2020", "FEB 14, 2020", "FEB 12, 2020", "FEB 10, 2020", "JAN 23, 2020", "FEB 19, 2020", "JAN 14, 2020", "JAN 3, 2020", "DEC 26, 2019", "DEC 19, 2019", "DEC 11, 2019", "DEC 10, 2019", "JAN 21, 2020", "DEC 9, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "NOV 26, 2019", "NOV 26, 2019", "NOV 24, 2019", "DEC 10, 2019", "NOV 4, 2019", "NOV 1, 2019", "NOV 1, 2019", "NOV 1, 2019", "OCT 30, 2019", "OCT 14, 2019", "OCT 3, 2019", "NOV 11, 2019", "SEP 14, 2019", "SEP 9, 2019", "AUG 23, 2019", "AUG 22, 2019", "AUG 12, 2019", "AUG 12, 2019", "AUG 7, 2019", "SEP 26, 2019", "AUG 1, 2019", "JUL 9, 2019", "JUL 7, 2019", "JUN 26, 2019", "JUN 21, 2019", "JUN 20, 2019", "JUN 15, 2019", "AUG 5, 2019", "JUN 10, 2019", "JUN 6, 2019", "JUN 4, 2019", "MAY 30, 2019", "MAY 19, 2019", "MAY 16, 2019", "APR 30, 2019", "JUN 10, 2019", "APR 29, 2019", "APR 27, 2019", "APR 22, 2019", "APR 19, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "APR 29, 2019", "APR 29, 2019", "APR 27, 2019", "APR 1, 2019", "MAR 31, 2019", "MAR 28, 2019", "MAR 26, 2019", "APR 9, 2019", "MAR 12, 2019", "MAR 11, 2019", "FEB 26, 2019", "FEB 25, 2019", "FEB 23, 2019", "FEB 22, 2019", "FEB 21, 2019", "MAR 23, 2019", "MAR 12, 2019", "MAR 11, 2019", "FEB 26, 2019", "FEB 25, 2019", "FEB 23, 2019", "FEB 22, 2019", "FEB 21, 2019", "FEB 13, 2019", "JAN 23, 2019", "JAN 22, 2019", "JAN 22, 2019", "JAN 12, 2019", "JAN 12, 2019", "JAN 11, 2019", "JAN 8, 2019", "JAN 23, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 3, 2019", "DEC 20, 2018", "DEC 19, 2018", "DEC 16, 2018", "JAN 7, 2019", "DEC 10, 2018", "DEC 6, 2018", "DEC 5, 2018", "DEC 4, 2018", "DEC 3, 2018", "DEC 1, 2018", "NOV 30, 2018", "DEC 14, 2018", "NOV 28, 2018", "NOV 17, 2018", "NOV 12, 2018", "NOV 9, 2018", "NOV 7, 2018", "NOV 7, 2018", "NOV 7, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 1, 2018", "NOV 1, 2018", "OCT 25, 2018", "OCT 11, 2018", "OCT 9, 2018", "OCT 8, 2018", "NOV 6, 2018", "SEP 21, 2018", "SEP 18, 2018", "SEP 14, 2018", "SEP 12, 2018", "SEP 10, 2018", "SEP 8, 2018", "SEP 7, 2018", "OCT 1, 2018", "SEP 6, 2018", "SEP 5, 2018", "AUG 31, 2018", "AUG 30, 2018", "AUG 30, 2018", "AUG 29, 2018", "AUG 27, 2018", "SEP 7, 2018", "AUG 13, 2018", "AUG 9, 2018", "AUG 8, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 21, 2018", "AUG 6, 2018", "AUG 3, 2018", "JUL 30, 2018", "JUL 30, 2018", "JUL 29, 2018", "JUL 26, 2018", "JUL 25, 2018", "AUG 6, 2018", "AUG 6, 2018", "JUL 11, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 9, 2018", "JUL 24, 2018", "JUL 23, 2018", "JUN 30, 2018", "JUN 27, 2018", "JUN 27, 2018", "JUN 22, 2018", "JUN 20, 2018", "JUN 19, 2018", "JUL 8, 2018", "JUL 1, 2018", "JUN 30, 2018", "JUN 27, 2018", "JUN 4, 2018", "JUN 3, 2018", "MAY 30, 2018", "JUN 15, 2018", "MAY 24, 2018", "MAY 24, 2018", "MAY 23, 2018", "MAY 14, 2018", "MAY 12, 2018", "MAY 11, 2018", "MAY 9, 2018", "MAY 30, 2018", "MAY 24, 2018", "MAY 24, 2018", "MAY 23, 2018", "APR 26, 2018", "APR 22, 2018", "APR 20, 2018", "APR 18, 2018", "MAY 4, 2018", "MAY 4, 2018", "APR 3, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 29, 2018", "MAR 29, 2018", "MAR 27, 2018", "APR 15, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 15, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 12, 2018", "MAR 9, 2018", "MAR 23, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 15, 2018", "MAR 13, 2018", "FEB 22, 2018", "FEB 20, 2018", "FEB 17, 2018", "MAR 8, 2018", "FEB 6, 2018", "FEB 5, 2018", "FEB 2, 2018", "FEB 1, 2018", "FEB 1, 2018", "JAN 30, 2018", "JAN 26, 2018", "FEB 9, 2018", "JAN 25, 2018", "JAN 24, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 25, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 16, 2018", "JAN 22, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 3, 2018", "JAN 2, 2018", "DEC 28, 2017", "JAN 11, 2018", "DEC 22, 2017", "DEC 20, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 15, 2017", "DEC 28, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 14, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 8, 2017", "DEC 11, 2017", "DEC 7, 2017", "DEC 5, 2017", "DEC 1, 2017", "NOV 30, 2017", "NOV 27, 2017", "NOV 24, 2017", "NOV 24, 2017", "DEC 8, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 13, 2017", "NOV 13, 2017", "NOV 12, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 20, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 1, 2017", "NOV 1, 2017", "NOV 1, 2017", "NOV 6, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 26, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 23, 2017", "NOV 1, 2017", "OCT 20, 2017", "OCT 19, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 10, 2017", "OCT 10, 2017", "OCT 23, 2017", "OCT 3, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "SEP 29, 2017", "SEP 29, 2017", "OCT 3, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 26, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 19, 2017", "SEP 28, 2017", "SEP 7, 2017", "SEP 6, 2017", "SEP 5, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "SEP 17, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 31, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 9, 2017", "AUG 7, 2017", "AUG 2, 2017", "JUL 28, 2017", "AUG 29, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 12, 2017", "JUL 9, 2017", "JUL 7, 2017", "JUL 5, 2017", "JUN 28, 2017", "JUL 21, 2017", "JUN 28, 2017", "JUN 25, 2017", "JUN 23, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 13, 2017", "JUN 28, 2017", "JUN 28, 2017", "JUN 25, 2017", "JUN 23, 2017", "JUN 16, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 11, 2017", "JUN 7, 2017", "JUN 7, 2017", "JUN 7, 2017", "JUN 7, 2017", "APR 6, 2017", "MAR 10, 2017", "MAY 5, 2017", "MAR 2, 2017", "FEB 28, 2017", "FEB 23, 2017", "FEB 15, 2017", "FEB 9, 2017", "FEB 8, 2017", "JAN 19, 2017", "MAR 6, 2017", "DEC 13, 2016", "DEC 9, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 18, 2016", "DEC 7, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 7, 2016", "NOV 17, 2016", "NOV 10, 2016", "NOV 9, 2016", "NOV 3, 2016", "NOV 2, 2016", "OCT 27, 2016", "OCT 26, 2016", "NOV 23, 2016", "OCT 25, 2016", "OCT 20, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 13, 2016", "OCT 25, 2016", "OCT 5, 2016", "OCT 3, 2016", "SEP 23, 2016", "SEP 22, 2016", "SEP 22, 2016", "SEP 16, 2016", "SEP 15, 2016", "OCT 11, 2016", "OCT 5, 2016", "OCT 3, 2016", "SEP 23, 2016", "SEP 22, 2016", "SEP 9, 2016", "SEP 9, 2016", "SEP 15, 2016", "SEP 15, 2016", "AUG 22, 2016", "AUG 12, 2016", "AUG 9, 2016", "AUG 8, 2016", "AUG 4, 2016", "JUL 30, 2016", "AUG 26, 2016", "AUG 24, 2016", "AUG 22, 2016", "JUL 20, 2016", "JUL 18, 2016", "JUL 13, 2016", "JUL 8, 2016", "JUL 27, 2016", "JUN 30, 2016", "JUN 28, 2016", "JUN 24, 2016", "JUN 10, 2016", "JUN 2, 2016", "MAY 25, 2016", "MAY 3, 2016", "JUL 8, 2016", "APR 20, 2016", "APR 20, 2016", "APR 20, 2016", "APR 12, 2016", "APR 7, 2016", "APR 6, 2016", "APR 6, 2016", "APR 21, 2016", "APR 20, 2016", "APR 20, 2016", "APR 20, 2016", "FEB 29, 2016", "FEB 16, 2016", "FEB 8, 2016", "APR 3, 2016", "FEB 1, 2016", "JAN 15, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 11, 2016", "FEB 2, 2016", "JAN 9, 2016", "JAN 7, 2016", "DEC 21, 2015", "DEC 16, 2015", "DEC 11, 2015", "DEC 10, 2015", "DEC 10, 2015", "JAN 11, 2016", "JAN 9, 2016", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 9, 2015", "DEC 8, 2015", "NOV 13, 2015", "NOV 10, 2015", "NOV 8, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 3, 2015", "NOV 20, 2015", "OCT 21, 2015", "OCT 6, 2015", "SEP 29, 2015", "SEP 28, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 21, 2015", "OCT 23, 2015", "OCT 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 14, 2015", "AUG 11, 2015", "AUG 10, 2015", "SEP 21, 2015", "AUG 7, 2015", "AUG 7, 2015", "JUL 30, 2015", "JUL 28, 2015", "JUL 19, 2015", "JUL 8, 2015", "JUL 2, 2015", "AUG 7, 2015", "JUN 16, 2015", "JUN 16, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 6, 2015", "JUN 5, 2015", "JUN 4, 2015", "JUN 23, 2015", "MAY 30, 2015", "MAY 28, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 24, 2015", "MAY 21, 2015", "MAY 21, 2015", "JUN 3, 2015", "MAY 6, 2015", "APR 28, 2015", "APR 27, 2015", "APR 22, 2015", "APR 6, 2015", "APR 5, 2015", "MAR 29, 2015", "MAY 8, 2015", "MAR 27, 2015", "MAR 12, 2015", "MAR 9, 2015", "FEB 26, 2015", "FEB 20, 2015", "FEB 19, 2015", "FEB 16, 2015", "MAR 28, 2015", "FEB 9, 2015", "FEB 5, 2015", "FEB 3, 2015", "JAN 28, 2015", "JAN 26, 2015", "JAN 21, 2015", "JAN 14, 2015", "FEB 13, 2015", "JAN 10, 2015", "JAN 4, 2015", "JAN 4, 2015", "JAN 3, 2015", "JAN 3, 2015", "DEC 30, 2014", "DEC 30, 2014", "JAN 12, 2015", "JAN 10, 2015", "DEC 23, 2014", "DEC 16, 2014", "DEC 11, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 24, 2014", "NOV 25, 2014", "OCT 24, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 20, 2014", "JUL 21, 2014", "JUL 15, 2014", "DEC 9, 2014", "JUL 8, 2014", "JUL 8, 2014", "JUL 8, 2014", "JUN 20, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUL 9, 2014", "MAY 20, 2014", "MAY 15, 2014", "APR 10, 2014", "APR 7, 2014", "MAR 12, 2014", "FEB 28, 2014", "FEB 7, 2014", "JUN 16, 2014", "DEC 26, 2013", "NOV 7, 2013", "JUN 24, 2013", "JUN 18, 2013", "JUN 17, 2013", "JUN 4, 2013", "MAY 14, 2013", "DEC 26, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/first-week-of-february-2021-options-trading-for-bluebird-bio-blue-2020-06-19", "https://www.nasdaq.com/articles/analysts-expect-10-gains-ahead-for-bbh-2020-06-18", "https://www.nasdaq.com/articles/better-buy%3A-crispr-therapeutics-vs.-sangamo-therapeutics-2020-06-14", "https://www.nasdaq.com/articles/bluebird-bio-reports-dramatic-improvement-in-sickle-cell-patients-with-lentiglobin-gene", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-gilead-sciences-2020-06-11", "https://www.nasdaq.com/articles/fda-mishaps-have-investors-asking-whats-going-on-with-bluebird-bio-2020-05-22", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dynavax-technologies-arbutus-biopharama-flotek-2020-05-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-18-2020%3A-jnjvirarnablue-2020-05-18", "https://www.nasdaq.com/articles/first-week-of-february-2021-options-trading-for-bluebird-bio-blue-2020-06-19", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-centric-brands-fulgent-genetics-moderna-2020-05-18-0", "https://www.nasdaq.com/articles/legend-biotech-makes-plans-to-ipo-with-backing-from-johnson-johnson-2020-05-14", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-akers-biosciences-comstock-virtusa-2020-05-14", "https://www.nasdaq.com/articles/fda-snubs-bmy-and-blue-stocks-that-moved-on-asco-abstracts-arvn-ctmx-mgnx-2020-05-13", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cornerstone-building-aerpio-pharma-j.c.-penney-2020-05-13", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-exelixis-2020-05-13", "https://www.nasdaq.com/articles/bristol-myers-squibb-receives-a-refuse-to-file-letter-for-an-experimental-cancer-therapy", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-18-2020%3A-virarnablue-2020-05-18", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-aerpio-pharma-j.c.-penney-bluebird-bio-2020-05-13", "https://www.nasdaq.com/articles/u.s.-fda-declines-to-review-bristol-myers-bluebird-therapy-for-multiple-myeloma-2020-05-13", "https://www.nasdaq.com/articles/u.s.-fda-decides-to-not-review-bristol-myers-bluebird-therapy-for-multiple-myeloma-2020-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-11-2020%3A-plxapopzyneblue-2020-05-11", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-11-2020%3A-apop-zyne-blue-bmy-2020-05-11", "https://www.nasdaq.com/articles/bristol-myers-squibb-offers-bluebird-bio-a-%24200-million-royalty-buyout-2020-05-11", "https://www.nasdaq.com/articles/bristol-myers-to-pay-bluebird-%24200-mln-for-future-royalties-on-cancer-therapies-2020-05-11", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-aerpio-pharma-j.c.-penney-genocea-bio-2020-05-13", "https://www.nasdaq.com/articles/better-buy%3A-crispr-therapeutics-vs.-bluebird-bio-2020-04-30", "https://www.nasdaq.com/articles/how-these-15-stock-suggestions-fared-against-the-market-2020-04-28", "https://www.nasdaq.com/articles/why-bluebird-bio-stock-soared-today-2020-04-09", "https://www.nasdaq.com/articles/bluebird-bio-is-now-oversold-blue-2020-04-01", "https://www.nasdaq.com/articles/so-your-biotech-announced-positive-phase-3-results-celebrating-could-be-premature-2020-04", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bristol-myers-squibb-and-bluebird-bio-are-getting-hammered", "https://www.nasdaq.com/articles/why-anaptysbio-bluebird-bio-and-exelixis-shares-rebounded-last-friday-2020-03-15", "https://www.nasdaq.com/articles/bristol-myers-to-pay-%24200-mln-to-bluebird-for-royalty-obligations-2020-05-11", "https://www.nasdaq.com/articles/hematology-focused-biotech-imara-to-ipo-soon-2020-03-06", "https://www.nasdaq.com/articles/is-bluebird-bio-a-millionaire-making-biotech-2020-03-04", "https://www.nasdaq.com/articles/why-so-many-biotechs-are-scrambling-to-develop-a-drug-for-the-same-rare-disease-2020-02-23", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2020-02-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-19-2020%3A-clrbhqyctsoblue-2020-02-19", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-unh-hqy-blue-2020-02-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-19-2020%3A-hqyctsoblue-2020-02-19", "https://www.nasdaq.com/articles/why-biotech-stocks-anaptysbio-bluebird-bio-and-editas-medicine-are-sinking-today-2020-03", "https://www.nasdaq.com/articles/why-bluebird-bios-q4-results-really-dont-matter-2020-02-19", "https://www.nasdaq.com/articles/bluebird-bio-beats-its-q4-revenue-target-but-misses-on-eps-2020-02-18", "https://www.nasdaq.com/articles/3-best-biotech-stocks-to-buy-for-the-next-decade-2020-02-16", "https://www.nasdaq.com/articles/analysts-predict-19-upside-for-fbt-2020-02-14", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-gilead-sciences-2020-02-12", "https://www.nasdaq.com/articles/bristol-myers-squibb-stock-is-too-cheap-to-ignore-2020-02-10", "https://www.nasdaq.com/articles/first-week-of-march-20th-options-trading-for-bluebird-bio-blue-2020-01-23", "https://www.nasdaq.com/articles/stock-alert%3A-bluebird-bio-stock-down-8-on-mixed-q4-results-2020-02-19", "https://www.nasdaq.com/articles/analysts-forecast-14-gains-ahead-for-the-holdings-of-bbh-2020-01-14", "https://www.nasdaq.com/articles/3-beaten-up-biotech-stocks-that-just-got-more-enticing-2020-01-03", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-cqqq-fbt-2019-12-26", "https://www.nasdaq.com/articles/the-top-biotech-stocks-to-watch-following-ash-2019-2019-12-19", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-ath-wmb-blue-2019-12-11", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-shares-jumped-almost-12-today-2019-12-10", "https://www.nasdaq.com/articles/fda-puts-glaxosmithklines-blood-cancer-drug-in-the-fast-lane-2020-01-21", "https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday%3A-chwy-sfix-shop-2019-12-09", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-0", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-1", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05", "https://www.nasdaq.com/articles/is-crispr-therapeutics-the-best-gene-editing-stock-right-now-2019-11-26", "https://www.nasdaq.com/articles/crispr-vs.-gene-therapy-round-1%3A-what-investors-need-to-know-2019-11-26", "https://www.nasdaq.com/articles/why-im-holding-on-to-my-bristol-myers-squibb-shares-now-that-the-celgene-acquisition-has", "https://www.nasdaq.com/articles/is-bluebird-bio-a-buy-2019-12-10", "https://www.nasdaq.com/articles/the-implied-analyst-12-month-target-for-osiz-2019-11-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-01-2019%3A-bgneamgnamedblue-2019-11-01-0", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-01-2019%3A-bgneamgnamedblue-2019-11-01", "https://www.nasdaq.com/articles/bgne-soars-drna-hits-new-high-on-roche-deal-fda-heeds-rephs-request-2019-11-01", "https://www.nasdaq.com/articles/3-reasons-crispr-therapeutics-stock-can-reach-record-highs-again-2019-10-30", "https://www.nasdaq.com/articles/why-did-the-market-whack-this-ipo-2019-10-14", "https://www.nasdaq.com/articles/3-cancer-fighting-drug-stocks-to-buy-right-now-2019-10-03", "https://www.nasdaq.com/articles/mondays-etf-with-unusual-volume%3A-iwb-2019-11-11", "https://www.nasdaq.com/articles/week-ahead-in-pharmaceuticals%3A-7-stocks-to-watch-aimt-lxrx-txg...-2019-09-14", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-fell-21.3-in-august-2019-09-09", "https://www.nasdaq.com/articles/bluebird-bio-enters-oversold-territory-2019-08-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-22-2019%3A-bluecnmdntrartrx-2019-08-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-12-2019%3A-solymlndorgsblue-2019-08-12", "https://www.nasdaq.com/articles/health-care-sector-update-for-08-12-2019%3A-mlndorgsblue-2019-08-12", "https://www.nasdaq.com/articles/bluebird-bio-prepares-for-launch-2019-08-07", "https://www.nasdaq.com/articles/oversold-conditions-for-bluebird-bio-blue-2019-09-26", "https://www.nasdaq.com/articles/iyhs-underlying-holdings-imply-14-gain-potential-2019-08-01", "https://www.nasdaq.com/articles/tuesdays-etf-movers%3A-fbt-xme-2019-07-09", "https://www.nasdaq.com/articles/is-bluebird-bio-a-buy-2019-07-07", "https://www.nasdaq.com/articles/first-week-of-blue-february-2020-options-trading-2019-06-26", "https://www.nasdaq.com/articles/where-will-bluebird-bio-be-in-1-year-2019-06-21", "https://www.nasdaq.com/articles/what-should-celgenes-investors-do-with-everything-bristol-meyer-squibb-is-giving-them-2019", "https://www.nasdaq.com/articles/is-%241.8-million-for-bluebird-bios-new-gene-therapy-ridiculous-2019-06-15", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-psmt-anet-blue-2019-08-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-10-2019%3A-bluetlryonce-2019-06-10", "https://www.nasdaq.com/articles/top-5-stocks-fight-against-cancer-2019-06-06", "https://www.nasdaq.com/articles/its-official%3A-bluebird-bio-gets-green-light-game-changing-gene-therapy-2019-06-04", "https://www.nasdaq.com/articles/11-biotech-stocks-put-your-radar-soon-2019-05-30", "https://www.nasdaq.com/articles/top-5-new-drug-launches-2019-and-biotech-stocks-could-win-big-2019-05-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-16-2019%3A-bluemrtxagioedapamgn-2019-05-16", "https://www.nasdaq.com/articles/5-biotech-stocks-for-a-long-lived-portfolio-2019-04-30", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-10-2019%3A-rwlktlryblueonce-2019-06-10", "https://www.nasdaq.com/articles/20-high-growth-stocks-next-20-years-2019-04-29", "https://www.nasdaq.com/articles/how-medicare-rule-change-could-bring-car-t-stocks-back-life-2019-04-27", "https://www.nasdaq.com/articles/why-you-shouldnt-count-regeneron-stock-out-2019-04-22", "https://www.nasdaq.com/articles/top-gene-sequencing-stocks-2019-2019-04-19", "https://www.nasdaq.com/articles/heres-why-shares-bluebird-bio-slumped-today-2019-04-17", "https://www.nasdaq.com/articles/blue-makes-notable-cross-below-critical-moving-average-2019-04-17", "https://www.nasdaq.com/articles/blue-makes-notable-cross-below-critical-moving-average-2019-04-17-0", "https://www.nasdaq.com/articles/analysts-expect-14-gains-ahead-holdings-rxl-2019-04-29", "https://www.nasdaq.com/articles/20-high-growth-stocks-next-20-years-2019-04-29", "https://www.nasdaq.com/articles/how-medicare-rule-change-could-bring-car-t-stocks-back-life-2019-04-27", "https://www.nasdaq.com/articles/commit-purchase-bluebird-bio-105-earn-133-using-options-2019-04-01", "https://www.nasdaq.com/articles/2-blockbuster-gene-therapy-programs-watch-2019-2019-03-31", "https://www.nasdaq.com/articles/iwfs-underlying-holdings-imply-10-gain-potential-2019-03-28", "https://www.nasdaq.com/articles/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review-2019-03-26", "https://www.nasdaq.com/articles/why-bluebird-bio-could-deliver-miracles-genetic-disease-patients-2019-04-09", "https://www.nasdaq.com/articles/celgene-celg-submits-application-for-ms-drug-in-europe-2019-03-12", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-gained-163-february-2019-03-11", "https://www.nasdaq.com/articles/stocked-war-chest-bluebird-bio-presses-2019-02-26", "https://www.nasdaq.com/articles/bluebird-bio-breaks-above-200-day-moving-average-bullish-blue-2019-02-25", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-vs-gilead-sciences-2019-02-23", "https://www.nasdaq.com/articles/bluebird-blue-q4-earnings-beat-estimates-revenues-up-y-y-2019-02-22", "https://www.nasdaq.com/articles/bluebird-bio-blue-reports-q4-loss-tops-revenue-estimates-2019-02-21", "https://www.nasdaq.com/articles/why-is-bluebird-blue-up-15.3-since-last-earnings-report-2019-03-23", "https://www.nasdaq.com/articles/celgene-celg-submits-application-for-ms-drug-in-europe-2019-03-12", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-gained-163-february-2019-03-11", "https://www.nasdaq.com/articles/stocked-war-chest-bluebird-bio-presses-2019-02-26", "https://www.nasdaq.com/articles/bluebird-bio-breaks-above-200-day-moving-average-bullish-blue-2019-02-25", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-vs-gilead-sciences-2019-02-23", "https://www.nasdaq.com/articles/bluebird-blue-q4-earnings-beat-estimates-revenues-up-y-y-2019-02-22", "https://www.nasdaq.com/articles/bluebird-bio-blue-reports-q4-loss-tops-revenue-estimates-2019-02-21", "https://www.nasdaq.com/articles/earnings-preview%3A-bluebird-bio-blue-q4-earnings-expected-to-decline-2019-02-13", "https://www.nasdaq.com/articles/health-care-sector-update-01232019-bluecnmdathxblph-2019-01-23", "https://www.nasdaq.com/articles/heres-why-crispr-therapeutics-stock-fell-today-2019-01-22", "https://www.nasdaq.com/articles/should-you-sell-crispr-therapeutics-following-analyst-downgrade-2019-01-22", "https://www.nasdaq.com/articles/heres-what-pushed-bluebird-bio-stock-down-443-2018-2019-01-12", "https://www.nasdaq.com/articles/3-biotech-stocks-watch-2019-2019-01-12", "https://www.nasdaq.com/articles/notable-friday-option-activity-x-c-blue-2019-01-11", "https://www.nasdaq.com/articles/celgene-celg-provides-guidance-for-2019-updates-pipeline-2019-01-08", "https://www.nasdaq.com/articles/5-best-biotech-bets-likely-to-outperform-estimates-in-q4-2019-01-23", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-shares-got-knocked-down-193-december-2019-01-04", "https://www.nasdaq.com/articles/bristol-myers-becomes-cancer-fighting-giant-celgene-buyout-2019-01-04", "https://www.nasdaq.com/articles/heres-what-bristol-myers-squibb-will-look-after-acquiring-celgene-2019-01-04", "https://www.nasdaq.com/articles/bristol-myers-bulks-74-bln-deal-buy-celgene-2019-01-03", "https://www.nasdaq.com/articles/bluebird-bio-enters-oversold-territory-blue-2018-12-20", "https://www.nasdaq.com/articles/forget-bluebird-bio-amgen-better-biotech-stock-2018-12-19", "https://www.nasdaq.com/articles/2-sets-disasters-biotech-will-pay-2019-2018-12-16", "https://www.nasdaq.com/articles/heres-why-crispr-therapeutics-tanked-255-december-2019-01-07", "https://www.nasdaq.com/articles/why-crsp-stock-has-added-layers-risk-2018-12-10", "https://www.nasdaq.com/articles/dow-drops-352-points-because-way-more-trade-war-2018-12-06", "https://www.nasdaq.com/articles/can-celgene-and-bluebird-bio-survive-two-pronged-attack-2018-12-05", "https://www.nasdaq.com/articles/global-blood-therapeutics-voxelotor-on-faster-approval-path-2018-12-04", "https://www.nasdaq.com/articles/celgene-celg-announces-various-cancer-data-at-ash-2018-2018-12-03", "https://www.nasdaq.com/articles/top-biotech-stocks-watch-ash-2018-2018-12-01", "https://www.nasdaq.com/articles/notable-friday-option-activity-blue-azo-rmti-2018-11-30", "https://www.nasdaq.com/articles/notable-friday-option-activity-blue-myl-bel-2018-12-14", "https://www.nasdaq.com/articles/celgene-bluebirds-car-t-therapy-study-completes-enrollment-2018-11-28", "https://www.nasdaq.com/articles/my-top-3-favorite-clinical-stage-biotech-stocks-buy-2018-11-17", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-iwp-2018-11-12", "https://www.nasdaq.com/articles/waiting-bluebird-bio-sing-ash-2018-11-09", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-fell-214-october-2018-11-07", "https://www.nasdaq.com/articles/3-cancer-stocks-watch-december-2018-11-07", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-november-2018-11-07", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-pipeline-updates-from-celg-vrtx-zfgn-plunges-on-hold-news-2018-11", "https://www.nasdaq.com/articles/celgene-bluebirds-car-t-therapy-study-completes-enrollment-2018-11-28", "https://www.nasdaq.com/articles/bluebird-bio-blue-reports-q3-loss-tops-revenue-estimates-2018-11-01", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-jumped-135-today-2018-11-01", "https://www.nasdaq.com/articles/celgene-celg-tops-q3-earnings-sales-estimates-ups-view-2018-10-25", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-dropped-133-september-2018-10-11", "https://www.nasdaq.com/articles/celgenes-otezla-meets-goal-in-scalp-plaque-psoriasis-study-2018-10-09", "https://www.nasdaq.com/articles/nobel-prize-cancer-immunotherapy-biotech-etfs-buy-2018-10-08", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings-beat-estimates-revenues-in-line-2018-11-06", "https://www.nasdaq.com/articles/micron-slumps-att-rises-dow-targets-another-new-high-2018-09-21", "https://www.nasdaq.com/articles/december-21st-options-now-available-bluebird-bio-blue-2018-09-18", "https://www.nasdaq.com/articles/why-bluebird-and-celgene-should-worry-about-amgens-latest-clinical-victory-2018-09-14", "https://www.nasdaq.com/articles/bluebird-bio-stock-may-have-upside-least-60-percent-2018-09-12", "https://www.nasdaq.com/articles/notable-monday-option-activity-blue-mcft-sfly-2018-09-10", "https://www.nasdaq.com/articles/now-good-time-buy-celgene-2018-09-08", "https://www.nasdaq.com/articles/celgenes-ceo-wants-make-biotechs-best-selling-drug-obsolete-heres-why-thats-great", "https://www.nasdaq.com/articles/first-week-may-2019-options-trading-bluebird-bio-blue-2018-10-01", "https://www.nasdaq.com/articles/bluebird-blue-reports-updated-data-on-lenti-d-gene-therapy-2018-09-06", "https://www.nasdaq.com/articles/3-hot-biotech-stocks-set-to-explode-2018-09-05", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-panw-bby-blue-2018-08-31", "https://www.nasdaq.com/articles/software-and-biotech-are-eating-world-2018-08-30", "https://www.nasdaq.com/articles/o-canadawere-waiting-you-2018-08-30", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-08-29", "https://www.nasdaq.com/articles/play-the-future-of-gene-therapy-with-these-5-biotech-stocks-2018-08-27", "https://www.nasdaq.com/articles/upcoming-earnings-watch-kr-play-tlrd-2018-09-07", "https://www.nasdaq.com/articles/turkey-ruins-week-dow-sp-2018-08-13", "https://www.nasdaq.com/articles/carl-icahn-fires-shots-express-scripts-2018-08-09", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-shines-blue-surges-once-plunges-2018-08-08", "https://www.nasdaq.com/articles/bluebird-bio-stock-is-for-long-term-investors-only-2018-08-06", "https://www.nasdaq.com/articles/why-bluebird-bio-blue-stock-gaining-today-2018-08-06", "https://www.nasdaq.com/articles/morning-movers-intel-drops-qualcomm-rises-bluebird-flies-2018-08-06", "https://www.nasdaq.com/articles/notable-monday-option-activity-tru-blue-cvgi-2018-08-06", "https://www.nasdaq.com/articles/is-celgene-set-to-see-improved-results-in-the-second-half-2018-08-21", "https://www.nasdaq.com/articles/t-mobile-sprint-pepsi-ceo-departs-jamie-dimons-latest-wisdom-more-free-lunch-2018-08-06", "https://www.nasdaq.com/articles/bluebird-blue-q2-loss-wider-than-expected-revenues-miss-2018-08-03", "https://www.nasdaq.com/articles/whats-in-store-for-celldex-cldx-this-earnings-season-2018-07-30", "https://www.nasdaq.com/articles/whats-in-the-cards-for-humana-hum-stock-in-q2-earnings-2018-07-30", "https://www.nasdaq.com/articles/can-celgenes-most-important-drugs-keep-growing-2018-07-29", "https://www.nasdaq.com/articles/celgene-celg-beats-q2-earnings-sales-estimates-ups-view-2018-07-26", "https://www.nasdaq.com/articles/did-top-biotech-stock-just-go-sale-2018-07-25", "https://www.nasdaq.com/articles/bluebird-bio-prepares-its-transition-commercial-company-2018-08-06", "https://www.nasdaq.com/articles/t-mobile-sprint-pepsi-ceo-departs-jamie-dimons-latest-wisdom-more-free-lunch-2018-08-06", "https://www.nasdaq.com/articles/celgene-reports-positive-data-on-tecentriq-abraxane-study-2018-07-11", "https://www.nasdaq.com/articles/financial-exchange-stock-talk-joe-mccann-loxo-oncology-and-bluebird-bio-2018-07-10", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-eqwm-2018-07-10", "https://www.nasdaq.com/articles/celgene-acceleron-report-positive-data-on-thalassemia-drug-2018-07-10", "https://www.nasdaq.com/articles/celgene-celg-down-21-so-far-in-2018%3A-what-lies-ahead-2018-07-09", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-inc-down-today-2018-07-24", "https://www.nasdaq.com/articles/2-most-wildly-overvalued-biotech-stocks-right-now-2018-07-01", "https://www.nasdaq.com/articles/celgene-investors-breathe-sigh-relief-after-accelerons-success-2018-06-30", "https://www.nasdaq.com/articles/iwn-umpq-blue-wtfc-etf-inflow-alert-2018-06-27", "https://www.nasdaq.com/articles/why-sangamo-therapeutics-and-bluebird-bio-slipped-lower-today-2018-06-27", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-blue-2018-06-22", "https://www.nasdaq.com/articles/first-week-blue-february-2019-options-trading-2018-06-20", "https://www.nasdaq.com/articles/morning-movers-dow-tumbles-360-points-bluebird-bio-verizon-rise-2018-06-19", "https://www.nasdaq.com/articles/why-bluebird-bios-shares-have-tumbled-119-2018-so-far-2018-07-08", "https://www.nasdaq.com/articles/2-most-wildly-overvalued-biotech-stocks-right-now-2018-07-01", "https://www.nasdaq.com/articles/celgene-investors-breathe-sigh-relief-after-accelerons-success-2018-06-30", "https://www.nasdaq.com/articles/iwn-umpq-blue-wtfc-etf-inflow-alert-2018-06-27", "https://www.nasdaq.com/articles/celgene-presents-data-on-car-t-therapy-revlimid-pomalyst-2018-06-04", "https://www.nasdaq.com/articles/asco18-weekend-surprises-2018-06-03", "https://www.nasdaq.com/articles/something-borrowed-something-blue-volume-2-its-been-roller-coaster-ride-blue-shareholders", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-outflow-2018-06-15", "https://www.nasdaq.com/articles/bluebirds-lenti-d-gets-breakthrough-therapy-status-from-fda-2018-05-24", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-2018-05-24", "https://www.nasdaq.com/articles/interesting-blue-put-and-call-options-july-20th-2018-05-23", "https://www.nasdaq.com/articles/iwm-nktr-grub-blue-large-inflows-detected-etf-2018-05-14", "https://www.nasdaq.com/articles/better-buy-ziopharm-oncology-inc-vs-bluebird-bio-inc-2018-05-12", "https://www.nasdaq.com/articles/3-growth-stocks-deep-value-prices-2018-05-11", "https://www.nasdaq.com/articles/bluebird-bio-looks-data-ahead-2018-05-09", "https://www.nasdaq.com/articles/something-old-something-new-something-borrowed-volume-2-particularly-motley-podcast-2018", "https://www.nasdaq.com/articles/bluebirds-lenti-d-gets-breakthrough-therapy-status-from-fda-2018-05-24", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-2018-05-24", "https://www.nasdaq.com/articles/can-celgene-celg-keep-its-earnings-streak-alive-in-q1-2018-05-01", "https://www.nasdaq.com/articles/iwm-nktr-grub-blue-etf-outflow-alert-2018-04-26", "https://www.nasdaq.com/articles/2-beta-thalassemia-drugs-are-fast-approaching-finish-line-2018-04-22", "https://www.nasdaq.com/articles/bluebird-bio-one-step-closer-its-first-commercial-drug-2018-04-20", "https://www.nasdaq.com/articles/iwm-blue-mksi-cw-large-inflows-detected-etf-2018-04-18", "https://www.nasdaq.com/articles/iwm-nktr-blue-grub-etf-outflow-alert-2018-05-04", "https://www.nasdaq.com/articles/celgene-celg-q1-earnings-sales-beat-on-revlimid-strength-2018-05-04", "https://www.nasdaq.com/articles/celgene-celg-president-and-coo-to-step-down%3A-whats-ahead-2018-04-03", "https://www.nasdaq.com/articles/relative-strength-alert-bluebird-bio-2018-04-02", "https://www.nasdaq.com/articles/iwm-blue-cw-azpn-large-outflows-detected-etf-2018-04-02", "https://www.nasdaq.com/articles/celgene-celg-up-on-deal-with-bluebird-for-car-t-candidate-2018-03-29", "https://www.nasdaq.com/articles/analysts-predict-12-upside-holdings-fny-2018-03-29", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-bac-blue-cmi-2018-03-27", "https://www.nasdaq.com/articles/bluebird-bio-inc-buy-dip-2018-04-15", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-biogen-inc-2018-03-22", "https://www.nasdaq.com/articles/my-favorite-biotech-stock-buy-sale-2018-03-21", "https://www.nasdaq.com/articles/vanguard-small-cap-growth-etf-experiences-big-inflow-2018-03-15", "https://www.nasdaq.com/articles/near-3-year-low-celgene-stock-buy-2018-03-13", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-sarepta-therapeutics-bluebird-bio-editas", "https://www.nasdaq.com/articles/why-sarepta-srpt-jumped-and-we-sold-2018-03-12", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-sangamo-bluebird-editas-sarepta-and-juno-2018", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vbk-xpo-blue-cprt-2018-03-23", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-biogen-inc-2018-03-22", "https://www.nasdaq.com/articles/my-favorite-biotech-stock-buy-sale-2018-03-21", "https://www.nasdaq.com/articles/vanguard-small-cap-growth-etf-experiences-big-inflow-2018-03-15", "https://www.nasdaq.com/articles/near-3-year-low-celgene-stock-buy-2018-03-13", "https://www.nasdaq.com/articles/bluebird-bio-updates-plans-year-ahead-2018-02-22", "https://www.nasdaq.com/articles/iwm-vixm-big-etf-outflows-2018-02-20", "https://www.nasdaq.com/articles/how-celgene-hopes-cash-car-t-2018-02-17", "https://www.nasdaq.com/articles/healthcare-heroes-arent-done-yet-2018-03-08", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-soared-15-january-2018-02-06", "https://www.nasdaq.com/articles/heres-why-global-blood-therapeutics-inc-soared-471-january-2018-02-05", "https://www.nasdaq.com/articles/3-top-biotherapeutics-stocks-buy-now-2018-02-02", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-outflow-2018-02-01", "https://www.nasdaq.com/articles/can-crispr-and-3-small-biotech-companies-cure-10000-diseases-2018-02-01", "https://www.nasdaq.com/articles/celgene-looking-good-plans-more-growth-2018-01-30", "https://www.nasdaq.com/articles/first-week-march-16th-options-trading-bluebird-bio-blue-2018-01-26", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-inflow-2018-02-09", "https://www.nasdaq.com/articles/will-2018-be-bellicum-pharmaceuticals-incs-best-year-yet-2018-01-25", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-cvlt-nav-blue-2018-01-24", "https://www.nasdaq.com/articles/bluebird-up-on-buyout-speculation-after-celgene-juno-deal-2018-01-23", "https://www.nasdaq.com/articles/celgene-celg-to-acquire-juno-therapeutics-for-%249-billion-2018-01-23", "https://www.nasdaq.com/articles/these-3-stocks-have-doubled-investors-money-2018-01-23", "https://www.nasdaq.com/articles/analysts-more-bullish-celgene-juno-sales-outlook-nags-2018-01-23", "https://www.nasdaq.com/articles/celgenes-9-billion-buyout-juno-it-good-deal-investors-2018-01-22", "https://www.nasdaq.com/articles/celgene-celg-q4-earnings-sales-beat-on-solid-revlimid-2018-01-25", "https://www.nasdaq.com/articles/bluebird-bio-blue-soars%3A-stock-adds-7.3-in-session-2018-01-18", "https://www.nasdaq.com/articles/healthcare-celgene-going-buy-juno-therapeutics-2018-01-18", "https://www.nasdaq.com/articles/why-celgenes-rumored-acquisition-juno-actually-makes-sense-2018-01-17", "https://www.nasdaq.com/articles/why-juno-therapeutics-stock-soaring-today-2018-01-17", "https://www.nasdaq.com/articles/is-celgene-celg-looking-to-take-over-juno-therapeutics-2018-01-17", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iwm-nktr-blue-sage-2018-01-16", "https://www.nasdaq.com/articles/juno-therapeutics-stock-rockets-report-celgene-buyout-talks-2018-01-16", "https://www.nasdaq.com/articles/why-bluebird-bio-soaring-119-today-2018-01-22", "https://www.nasdaq.com/articles/1887-bluebird-bio-stock-still-strong-buy-2018-01-11", "https://www.nasdaq.com/articles/what-bluebird-bio-wants-you-know-about-its-business-2018-01-11", "https://www.nasdaq.com/articles/celgene-provides-2017-preliminary-results-2018-view-2018-01-09", "https://www.nasdaq.com/articles/iwm-agnd-big-etf-outflows-2018-01-08", "https://www.nasdaq.com/articles/bluebird-bio-reaches-analyst-target-price-2018-01-03", "https://www.nasdaq.com/articles/heres-how-bluebird-bio-inc-crushed-it-2017-2018-01-02", "https://www.nasdaq.com/articles/2018-should-be-better-celgene-corporation-and-celg-stock-2017-12-28", "https://www.nasdaq.com/articles/heres-what-celgenes-management-just-said-about-its-future-2018-01-11", "https://www.nasdaq.com/articles/4-biotech-stocks-that-more-than-doubled-this-year-2017-12-22", "https://www.nasdaq.com/articles/what-expect-celgene-corporation-2018-2017-12-20", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-iwn-mtg-stl-blue-2017-12-19", "https://www.nasdaq.com/articles/why-juno-therapeutics-stock-fell-last-week-2017-12-19", "https://www.nasdaq.com/articles/celgene-stock-huge-exciting-car-t-news-2017-12-19", "https://www.nasdaq.com/articles/celgene-shareholders-excited-car-t-news-2017-12-19", "https://www.nasdaq.com/articles/car-t-stocks-in-focus-with-ash-2017-meet%3A-gild-juno-more-2017-12-15", "https://www.nasdaq.com/articles/heres-where-things-went-wrong-celgene-corporation-2017-2017-12-28", "https://www.nasdaq.com/articles/iwm-enor-big-etf-outflows-2017-12-13", "https://www.nasdaq.com/articles/heres-why-everyones-so-excited-about-bluebird-bio-2017-12-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-ash-data-focus-gilead-buy-cell-design-labs-2017-12-13", "https://www.nasdaq.com/articles/5-biotech-buyout-candidates-2018-2017-12-13", "https://www.nasdaq.com/articles/biotech-stock-seen-cheapest-among-rivals-cancer-drugs-2017-12-13", "https://www.nasdaq.com/articles/company-news-for-dec-12-2017-2017-12-12", "https://www.nasdaq.com/articles/bluebirds-shares-jump-on-strong-data-for-car-t-therapy-2017-12-12", "https://www.nasdaq.com/articles/ash-2017-recap-these-were-big-winners-and-losers-2017-12-14", "https://www.nasdaq.com/articles/apple-leads-nasdaq-stocks-best-bitcoin-etf-trade-2017-12-11", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-stock-skyrocketed-today-2017-12-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-sbgi-blue-once-2017-12-11", "https://www.nasdaq.com/articles/biotech-stocks-soar-trial-data-hematology-conference-2017-12-11", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-3m-sell-communication-markets-division-900m", "https://www.nasdaq.com/articles/futures-trend-higher-upbeat-jobs-report-continues-fuel-gains-2017-12-11", "https://www.nasdaq.com/articles/bluebird-bio-stock-soars-unprecedented-blood-cancer-study-results-2017-12-11", "https://www.nasdaq.com/articles/ash-2017-car-t-wallops-blood-cancer-2017-12-12", "https://www.nasdaq.com/articles/apple-leads-nasdaq-stocks-best-bitcoin-etf-trade-2017-12-11", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-stock-skyrocketed-today-2017-12-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-sbgi-blue-once-2017-12-11", "https://www.nasdaq.com/articles/health-care-sector-update-12112017-atnxbluevtgn-2017-12-11", "https://www.nasdaq.com/articles/mid-afternoon-market-update-nasdaq-05-bluebird-bio-shares-spike-higher-2017-12-11", "https://www.nasdaq.com/articles/health-care-sector-update-12112017-bpmcbluevtgn-2017-12-11", "https://www.nasdaq.com/articles/why-biotech-stocks-may-wait-while-feeling-love-2017-12-08", "https://www.nasdaq.com/articles/morning-movers-bluebird-bio-solar-stocks-soar-paccar-falls-2017-12-11", "https://www.nasdaq.com/articles/heres-why-bluebird-bios-shares-soared-24-november-2017-12-07", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-inflow-2017-12-05", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2017-12-01", "https://www.nasdaq.com/articles/does-gileads-kite-acquisition-offer-new-buying-opportunity-2017-11-30", "https://www.nasdaq.com/articles/iwm-blue-nktr-mksi-large-inflows-detected-etf-2017-11-27", "https://www.nasdaq.com/articles/apple-strong-square-eyes-5th-week-1-reason-why-biotechs-arent-dead-yet-2017-11-24", "https://www.nasdaq.com/articles/car-t-therapy-space-2017-progress-report-2017-11-24", "https://www.nasdaq.com/articles/gilead-sciences-to-acquire-cell-design-labs-for-%24567-million-2017-12-08", "https://www.nasdaq.com/articles/iwm-blue-nktr-mksi-etf-inflow-alert-2017-11-17", "https://www.nasdaq.com/articles/celgene-car-t-therapy-gets-breakthrough-therapy-designation-2017-11-17", "https://www.nasdaq.com/articles/rare-quarterly-appearance-bluebird-bio-incs-management-2017-11-13", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-november-2017-11-13", "https://www.nasdaq.com/articles/5-irresistible-reasons-buy-celgene-stock-right-now-hint-1-its-dirt-cheap-2017-11-12", "https://www.nasdaq.com/articles/blue-crosses-above-average-analyst-target-2017-11-10", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwm-blue-cw-stl-2017-11-09", "https://www.nasdaq.com/articles/juno-therapeutics-back-new-data-slingshot-insights-idea-month-2017-11-20", "https://www.nasdaq.com/articles/morning-movers-valeant-climbs-sears-sinks-herbalife-drops-2017-11-03", "https://www.nasdaq.com/articles/3-reasons-its-smart-buy-celgenes-stock-now-2017-11-03", "https://www.nasdaq.com/articles/iwm-blue-mksi-stl-large-inflows-detected-etf-2017-11-02", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-inc-surging-again-today-2017-11-02", "https://www.nasdaq.com/articles/how-blood-disease-data-sent-these-2-biotech-stocks-flying-2017-11-01", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-vmw-prty-blue-2017-11-01", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2017-11-01", "https://www.nasdaq.com/articles/3-stocks-buy-better-tomorrow-2017-11-06", "https://www.nasdaq.com/articles/2-top-pharma-stocks-sale-week-2017-10-30", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-bluebird-bio-blue-2017-10-30", "https://www.nasdaq.com/articles/vanguard-health-care-fund-buys-6-new-stocks-3rd-quarter-2017-10-30", "https://www.nasdaq.com/articles/was-celgenes-third-quarter-really-crash-worthy-2017-10-26", "https://www.nasdaq.com/articles/why-agenus-inc-stock-briefly-popped-today-2017-10-23", "https://www.nasdaq.com/articles/commit-buy-bluebird-bio-85-earn-151-using-options-2017-10-23", "https://www.nasdaq.com/articles/gilead-drug-approval-fuels-interest-car-t-space-3-stocks-consider-2017-10-23", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-jumped-higher-today-2017-11-01", "https://www.nasdaq.com/articles/celgene-could-be-best-car-t-stock-buy-not-gilead-sciences-2017-10-20", "https://www.nasdaq.com/articles/does-gilead-now-have-new-multi-billion-dollar-franchise-2017-10-19", "https://www.nasdaq.com/articles/buying-and-selling-stocks-right-are-keys-top-mutual-funds-success-2017-10-16", "https://www.nasdaq.com/articles/celgene-blood-cancer-treatment-just-tip-its-disruptive-science-2017-10-16", "https://www.nasdaq.com/articles/kite-pharma-cancer-treatment-stands-out-hot-car-t-field-2017-10-16", "https://www.nasdaq.com/articles/iwm-blue-stl-azpn-etf-outflow-alert-2017-10-10", "https://www.nasdaq.com/articles/why-crispr-therapeutics-ag-stock-lost-ground-september-2017-10-10", "https://www.nasdaq.com/articles/3-gene-therapy-stocks-could-make-you-rich-2017-10-23", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-stock-gained-10-september-2017-10-03", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-stock-falling-today-2017-10-02", "https://www.nasdaq.com/articles/iwm-rfap-big-etf-outflows-2017-10-02", "https://www.nasdaq.com/articles/morning-movers-sarepta-jumps-bluebird-bio-drops-mgm-slumps-2017-10-02", "https://www.nasdaq.com/articles/why-bluebirds-downgrade-sent-these-two-rivals-skyrocketing-2017-10-02", "https://www.nasdaq.com/articles/morning-movers-conns-climbs-jb-hunt-soars-goldcorp-gains-2017-09-29", "https://www.nasdaq.com/articles/big-dose-healthy-news-sends-biotech-stocks-new-heights-2017-09-29", "https://www.nasdaq.com/articles/analysts-act-health-care-stocks-2017-10-03", "https://www.nasdaq.com/articles/why-blackberry-abbvie-and-bluebird-bio-jumped-today-2017-09-28", "https://www.nasdaq.com/articles/bluebird-hits-high-bullish-report-highlighting-blood-drugs-2017-09-28", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-2017-09-28", "https://www.nasdaq.com/articles/3-biotech-stocks-major-catalysts-october-2017-09-26", "https://www.nasdaq.com/articles/iwm-esgu-big-etf-inflows-2017-09-22", "https://www.nasdaq.com/articles/juno-therapeutics-inc-juno-stock%3A-to-buy-or-not-to-buy-2017-09-22", "https://www.nasdaq.com/articles/yes-juno-therapeutics-juno-just-became-a-great-car-t-trade-2017-09-19", "https://www.nasdaq.com/articles/stock-indexes-mixed-small-caps-lag-2017-09-28", "https://www.nasdaq.com/articles/5-things-youll-want-know-celgene-corporations-latest-presentation-2017-09-07", "https://www.nasdaq.com/articles/heres-what-lifted-bluebird-bio-inc-stock-40-higher-august-2017-09-06", "https://www.nasdaq.com/articles/iwm-kite-grub-blue-large-outflows-detected-etf-2017-09-05", "https://www.nasdaq.com/articles/gilead-buys-kite-future-car-t-and-visit-new-whole-foods-2017-09-01", "https://www.nasdaq.com/articles/5-top-performing-stocks-top-etf-august-2017-09-01", "https://www.nasdaq.com/articles/bluebird-bio-blue-looks-good%3A-stock-adds-11-in-session-2017-09-01", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-bbh-2017-08-31", "https://www.nasdaq.com/articles/dont-make-huge-mistake-celgene-2017-09-17", "https://www.nasdaq.com/articles/health-care-sector-update-08312017-nvoipxlstdy-2017-08-31", "https://www.nasdaq.com/articles/wednesdays-etf-movers-bbh-gdxj-2017-08-30", "https://www.nasdaq.com/articles/juno-bluebird-hot-acquisition-targets-after-kite-gilead-deal-2017-08-30", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-jumped-higher-today-2017-08-30", "https://www.nasdaq.com/articles/why-novatis-475k-car-t-cancer-treatment-actually-cheap-2017-08-30", "https://www.nasdaq.com/articles/bluebird-bio-reaches-analyst-target-price-2017-08-29", "https://www.nasdaq.com/articles/heres-what-else-gilead-sciences-gets-buying-kite-pharma-2017-08-29", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-continued-its-march-higher-again-today-2017-08-31", "https://www.nasdaq.com/articles/juno-therapeutics-juno-continues-gains-after-gilead-kite-acquisition-2017-08-29", "https://www.nasdaq.com/articles/holding-harvey-2017-08-29", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-and-juno-therapeutics-inc-shot-higher-today-2017-08-28", "https://www.nasdaq.com/articles/why-bluebird-bio-dipped-105-july-2017-08-09", "https://www.nasdaq.com/articles/bluebird-bio-pauses-during-2017-data-blitz-2017-08-07", "https://www.nasdaq.com/articles/3-reasons-best-yet-come-celgene-2017-08-02", "https://www.nasdaq.com/articles/celgene-corporation-continues-get-it-done-2017-07-28", "https://www.nasdaq.com/articles/indecision-wont-kill-you-it-will-take-your-money-2017-08-29", "https://www.nasdaq.com/articles/new-cancer-treatment-way-and-cancer-better-be-scared-2017-07-13", "https://www.nasdaq.com/articles/novartis-car-t-therapy-drug-recommended-by-fda-panel-2017-07-13", "https://www.nasdaq.com/articles/junior-freak-out-2017-07-12", "https://www.nasdaq.com/articles/billions-dollars-line-celgene-these-3-small-biotechs-2017-07-09", "https://www.nasdaq.com/articles/iwm-blue-gpt-hls-large-outflows-detected-etf-2017-07-07", "https://www.nasdaq.com/articles/how-conference-caused-bluebird-bios-shares-rocket-33-june-2017-07-05", "https://www.nasdaq.com/articles/etf-winner-1h17-and-its-top-5-stocks-2017-06-28", "https://www.nasdaq.com/articles/commit-buy-bluebird-bio-50-earn-104-using-options-2017-07-21", "https://www.nasdaq.com/articles/health-care-sector-update-06282017-bluespnccemi-2017-06-28", "https://www.nasdaq.com/articles/3-reasons-buy-celgene-stock-and-never-sell-2017-06-25", "https://www.nasdaq.com/articles/why-blackberry-sysco-and-bluebird-bio-slumped-today-2017-06-23", "https://www.nasdaq.com/articles/3-top-performing-biotech-stocks-week-2017-06-16", "https://www.nasdaq.com/articles/will-these-cutting-edge-cancer-killers-reignite-biotech-rally-2017-06-15", "https://www.nasdaq.com/articles/can-celgene-corporation-be-value-stock-2017-06-15", "https://www.nasdaq.com/articles/excitement-asco-tg-thereapeutics-loxo-oncology-and-bluebird-bio-2017-06-13", "https://www.nasdaq.com/articles/2-fastest-growing-biotech-stocks-2017-06-28", "https://www.nasdaq.com/articles/health-care-sector-update-06282017-bluespnccemi-2017-06-28", "https://www.nasdaq.com/articles/3-reasons-buy-celgene-stock-and-never-sell-2017-06-25", "https://www.nasdaq.com/articles/why-blackberry-sysco-and-bluebird-bio-slumped-today-2017-06-23", "https://www.nasdaq.com/articles/3-top-performing-biotech-stocks-week-2017-06-16", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-flew-higher-today-2017-06-06", "https://www.nasdaq.com/articles/notable-monday-option-activity-hain-urbn-blue-2017-06-05", "https://www.nasdaq.com/articles/what-investors-missed-market-last-week-2017-06-11", "https://www.nasdaq.com/articles/bluebird-bio-reaches-analyst-target-price-2017-06-07", "https://www.nasdaq.com/articles/3-promising-stocks-buy-now-2017-06-07", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-flew-higher-again-today-2017-06-07", "https://www.nasdaq.com/articles/why-hawaiian-holdings-mbia-and-bluebird-bio-jumped-today-2017-06-07", "https://www.nasdaq.com/articles/first-car-t-drugs-have-left-gate-2017-04-06", "https://www.nasdaq.com/articles/blue-crosses-above-average-analyst-target-2017-03-10", "https://www.nasdaq.com/articles/bluebird-bio-updates-investors-wait-2017-05-05", "https://www.nasdaq.com/articles/4-biotech-stocks-breaking-out-positive-drug-developments-2017-03-02", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-2017-02-28", "https://www.nasdaq.com/articles/bluebird-bio-inc-highlights-data-rich-2017-2017-02-23", "https://www.nasdaq.com/articles/these-4-stocks-are-breaking-out-2017-02-15", "https://www.nasdaq.com/articles/why-bluebird-bio-stock-surged-207-higher-january-2017-02-09", "https://www.nasdaq.com/articles/3-scorching-hot-biotech-stocks-are-they-buys-2017-02-08", "https://www.nasdaq.com/articles/commit-purchase-bluebird-bio-45-earn-222-using-options-2017-01-19", "https://www.nasdaq.com/articles/better-buy-bellicum-pharmaceuticals-inc-vs-bluebird-bio-inc-2017-03-06", "https://www.nasdaq.com/articles/better-buy-intrexon-corporation-vs-bluebird-bio-2016-12-13", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-inc-vs-kite-pharma-2016-12-09", "https://www.nasdaq.com/articles/wednesdays-etf-movers-gdxj-xbi-2016-12-07", "https://www.nasdaq.com/articles/wednesday-sector-laggards-drugs-biotechnology-stocks-2016-12-07", "https://www.nasdaq.com/articles/pre-market-most-active-dec-7-2016-ter-rad-mt-pbr-bac-vale-mu-aapl-tvix-tlt-xiv-blue-2016", "https://www.nasdaq.com/articles/why-flotek-industries-oxford-industries-and-bluebird-bio-slumped-today-2016-12-07", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-slipped-lower-today-2016-12-07", "https://www.nasdaq.com/articles/3-small-biotech-stocks-big-biotechs-2016-12-18", "https://www.nasdaq.com/articles/why-you-should-let-celgene-corporation-invest-your-money-2016-12-07", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-stock-soaring-today-2016-12-01", "https://www.nasdaq.com/articles/stock-futures-flat-ahead-manufacturing-data-2016-12-01", "https://www.nasdaq.com/articles/pre-market-most-active-dec-1-2016-vale-vcit-chk-wll-tln-pbr-vod-sdrl-blue-boja-xiv-tvix", "https://www.nasdaq.com/articles/why-general-motors-bluebird-bio-and-skechers-usa-jumped-today-2016-12-01", "https://www.nasdaq.com/articles/potentially-astounding-advance-multiple-myeloma-2016-12-01", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-rallying-today-2016-12-01", "https://www.nasdaq.com/articles/global-blood-therapeutics-short-sellers-could-be-ride-2016-12-07", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-bluebird-bio-2016-11-17", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-stock-got-crushed-october-2016-11-10", "https://www.nasdaq.com/articles/7276-million-reasons-bluebird-bio-inc-has-time-figure-it-out-2016-11-09", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-got-knocked-down-today-2016-11-03", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-november-2016-11-02", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-blue-2016-10-27", "https://www.nasdaq.com/articles/global-blood-therapeutics-incredible-value-price-2016-10-26", "https://www.nasdaq.com/articles/why-juno-therapeutics-inc-plummeted-today-2016-11-23", "https://www.nasdaq.com/articles/better-buy-celldex-therapeutics-inc-vs-bluebird-bio-inc-2016-10-25", "https://www.nasdaq.com/articles/commit-purchase-bluebird-bio-30-earn-14-using-options-2016-10-20", "https://www.nasdaq.com/articles/why-shares-bluebird-bio-inc-took-dive-today-2016-10-14", "https://www.nasdaq.com/articles/health-care-sector-update-10142016-blueenzeglt-2016-10-14", "https://www.nasdaq.com/articles/fridays-etf-movers-igv-xbi-2016-10-14", "https://www.nasdaq.com/articles/friday-sector-laggards-drugs-biotechnology-stocks-2016-10-14", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-vs-inovio-pharmaceuticals-2016-10-13", "https://www.nasdaq.com/articles/why-global-blood-therapeutics-incs-shares-are-soaring-today-2016-10-25", "https://www.nasdaq.com/articles/peek-under-hood-iyy-has-10-upside-2016-10-05", "https://www.nasdaq.com/articles/xbi-srpt-ions-blue-etf-inflow-alert-2016-10-03", "https://www.nasdaq.com/articles/xbi-srpt-blue-ions-etf-inflow-alert-2016-09-23", "https://www.nasdaq.com/articles/health-care-sector-update-09222016-aaapavxlblue-2016-09-22", "https://www.nasdaq.com/articles/health-care-sector-update-09222016-lgndavxlblue-2016-09-22", "https://www.nasdaq.com/articles/bluebird-bio-blue-in-focus%3A-stock-moves-11.4-higher-2016-09-16", "https://www.nasdaq.com/articles/xbi-ions-mdvn-blue-etf-inflow-alert-2016-09-15", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-stock-soared-374-september-2016-10-11", "https://www.nasdaq.com/articles/peek-under-hood-iyy-has-10-upside-2016-10-05", "https://www.nasdaq.com/articles/xbi-srpt-ions-blue-etf-inflow-alert-2016-10-03", "https://www.nasdaq.com/articles/xbi-srpt-blue-ions-etf-inflow-alert-2016-09-23", "https://www.nasdaq.com/articles/health-care-sector-update-09222016-aaapavxlblue-2016-09-22", "https://www.nasdaq.com/articles/3-reasons-bluebird-bio-inc-stock-dipped-137-august-2016-09-09", "https://www.nasdaq.com/articles/bluebird-bio-stock-up-on-start-of-phase-iii-lentiglobin-study-2016-09-09", "https://www.nasdaq.com/articles/3-stocks-to-watch-thursday%3A-viacom-inc.-viab-aerie-pharmaceuticals-inc-aeri-and-bluebird", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-blue-2016-08-24", "https://www.nasdaq.com/articles/xbi-ions-srpt-blue-etf-outflow-alert-2016-08-22", "https://www.nasdaq.com/articles/xbi-ions-srpt-blue-etf-inflow-alert-2016-08-12", "https://www.nasdaq.com/articles/bluebird-bio-inc-earnings-waiting-data-2016-08-09", "https://www.nasdaq.com/articles/health-care-sector-update-08082016-ptimeipchek-2016-08-08", "https://www.nasdaq.com/articles/bluebird-bio-inc-tumbles-94-after-reporting-wider-expected-q2-loss-2016-08-04", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-sale-2016-07-30", "https://www.nasdaq.com/articles/we-did-math-bbh-can-go-136-2016-08-26", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-blue-2016-08-24", "https://www.nasdaq.com/articles/xbi-ions-srpt-blue-etf-outflow-alert-2016-08-22", "https://www.nasdaq.com/articles/celgene-celg-jounce-strike-immunotherapy-collaboration-2016-07-20", "https://www.nasdaq.com/articles/could-be-next-big-pharma-buyout-2016-07-18", "https://www.nasdaq.com/articles/comeback-juno-juno-stock-fda-lifts-clinical-hold-2016-07-13", "https://www.nasdaq.com/articles/why-juno-therapeutics-juno-stock-plunging-31-today-2016-07-08", "https://www.nasdaq.com/articles/5-reasons-bluebird-bio-inc-took-flight-today-2016-07-27", "https://www.nasdaq.com/articles/141-reasons-love-biotech-stocks-2016-06-30", "https://www.nasdaq.com/articles/heres-why-bluebird-bios-shares-dropped-10-monday-2016-06-28", "https://www.nasdaq.com/articles/better-buy-agenus-inc-vs-bluebird-bio-2016-06-24", "https://www.nasdaq.com/articles/why-global-blood-therapeutics-inc-skyrocketed-and-bluebird-bio-inc-sank-today-2016-06-10", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-vs-inovio-pharmaceuticals-2016-06-02", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-bluebird-bio-2016-05-25", "https://www.nasdaq.com/articles/forget-bluebird-bio-inc-these-3-stocks-are-better-buys-2016-05-03", "https://www.nasdaq.com/articles/juno-juno-suffers-setback-pivotal-study-clinical-hold-2016-07-08", "https://www.nasdaq.com/articles/health-care-sector-update-04202016-oncsoclsblue-2016-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202016-hnsnoclsblue-2016-04-20", "https://www.nasdaq.com/articles/commit-buy-bluebird-bio-35-earn-221-annualized-using-options-2016-04-20", "https://www.nasdaq.com/articles/heres-why-bluebird-bios-stock-tumbled-march-2016-04-12", "https://www.nasdaq.com/articles/why-bluebird-bios-stock-jumped-129-wednesday-2016-04-07", "https://www.nasdaq.com/articles/anavex-life-sciences-stock-1-key-number-you-must-know-2016-04-06", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-2016-04-06", "https://www.nasdaq.com/articles/bluebird-bio-inc-takes-flight-towards-first-approval-2016-04-21", "https://www.nasdaq.com/articles/health-care-sector-update-04202016-oncsoclsblue-2016-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202016-hnsnoclsblue-2016-04-20", "https://www.nasdaq.com/articles/commit-buy-bluebird-bio-35-earn-221-annualized-using-options-2016-04-20", "https://www.nasdaq.com/articles/bluebird-bio-inc-waiting-ash-2016-02-29", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-juno-therapeutics-inc-and-alnylam-pharmaceuticals-inc-jumped-today", "https://www.nasdaq.com/articles/why-bluebird-bio-incs-stock-dropped-34-january-2016-02-08", "https://www.nasdaq.com/articles/could-be-next-big-pharma-buyout-2016-04-03", "https://www.nasdaq.com/articles/bluebird-bio-inc-takes-flight-2016-02-01", "https://www.nasdaq.com/articles/best-healthcare-stocks-2016-2016-01-15", "https://www.nasdaq.com/articles/kite-pharma-signs-deal-with-leiden-university-medical-center-2016-01-14", "https://www.nasdaq.com/articles/why-bluebird-bio-incs-stock-bounced-back-2016-01-13", "https://www.nasdaq.com/articles/weakness-seen-in-bluebird-blue-%3A-stock-plunges-19.5-2016-01-12", "https://www.nasdaq.com/articles/oversold-conditions-bluebird-bio-blue-2016-01-11", "https://www.nasdaq.com/articles/why-bluebird-bio-incs-stock-tanking-today-2016-01-11", "https://www.nasdaq.com/articles/4-top-ranked-biotech-stocks-sale-2016-02-02", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-turned-disappointing-2015-2016-01-09", "https://www.nasdaq.com/articles/heres-why-uniqure-nvs-stock-spiked-today-2016-01-07", "https://www.nasdaq.com/articles/bluebird-bio-inc-gene-therapy-still-hard-2015-12-21", "https://www.nasdaq.com/articles/bear-day-conns-conn-2015-12-16", "https://www.nasdaq.com/articles/clinical-data-whipsaws-bluebird-bio-inc-november-2015-12-11", "https://www.nasdaq.com/articles/thursday-1210-insider-buying-report-blue-lob-2015-12-10", "https://www.nasdaq.com/articles/bluebird-bio-ceo-buys-more-9000-shares-2015-12-10", "https://www.nasdaq.com/articles/mondays-etf-movers-xlp-xbi-2016-01-11", "https://www.nasdaq.com/articles/why-staples-office-depot-and-bluebird-bio-slumped-monday-2015-12-08", "https://www.nasdaq.com/articles/bluebird-bio-crashes-after-clinical-trial-update-2015-12-07", "https://www.nasdaq.com/articles/bluebird-bio-breaks-down-over-disappointing-clinical-update-2015-12-07", "https://www.nasdaq.com/articles/pre-market-most-active-dec-7-2015-gmcr-san-blue-pbr-kmi-tvix-fcau-sdrl-gbt-xiv-aa-aapl", "https://www.nasdaq.com/articles/health-care-sector-update-12072015-bluexbitthld-2015-12-07", "https://www.nasdaq.com/articles/notable-monday-option-activity-blue-enva-clr-2015-12-07", "https://www.nasdaq.com/articles/why-global-blood-therapeutics-inc-shares-are-tanking-today-2015-12-07", "https://www.nasdaq.com/articles/whats-next-bluebird-bio-2015-12-09", "https://www.nasdaq.com/articles/why-staples-office-depot-and-bluebird-bio-slumped-monday-2015-12-08", "https://www.nasdaq.com/articles/kite-pharma-kite-posts-narrower-expected-loss-3q-2015-11-13", "https://www.nasdaq.com/articles/kite-kite-report-3q-earnings-whats-store-2015-11-10", "https://www.nasdaq.com/articles/bluebird-bio-ash-puts-damper-earnings-2015-11-08", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-inc-crash-landed-today-2015-11-05", "https://www.nasdaq.com/articles/pre-market-most-active-nov-5-2015-away-fb-feye-blue-nvo-aapl-expe-bac-vale-pbr-bp-itub", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-flying-higher-2015-11-03", "https://www.nasdaq.com/articles/2-biotech-stocks-watch-december-2015-11-20", "https://www.nasdaq.com/articles/kite-kite-kte-c19-endorsed-for-eu-orphan-status-yet-again-2015-10-21", "https://www.nasdaq.com/articles/3-biotech-stocks-have-been-unfairly-beaten-down-2015-10-06", "https://www.nasdaq.com/articles/weakness-seen-in-bluebird-blue%3A-stock-tumbles-13.3-2015-09-29", "https://www.nasdaq.com/articles/interesting-blue-put-and-call-options-october-16th-2015-09-28", "https://www.nasdaq.com/articles/5-sell-ranked-biotechs-fell-more-5-today-2015-09-25", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-shares-slumped-again-2015-09-25", "https://www.nasdaq.com/articles/bluebird-bio-blue-shares-cross-below-200-dma-2015-09-21", "https://www.nasdaq.com/articles/5-high-risk-high-reward-stocks-were-watching-2015-10-23", "https://www.nasdaq.com/articles/kite-kite-kte-c19-endorsed-for-eu-orphan-status-yet-again-2015-10-21", "https://www.nasdaq.com/articles/3-biotech-stocks-could-be-buyout-targets-2015-08-21", "https://www.nasdaq.com/articles/bluebird-bio-blue-shares-cross-below-200-dma-2015-08-21", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-bluebird-bio-blue-2015-08-14", "https://www.nasdaq.com/articles/kite-pharma-2q-loss-wider-expected-pipeline-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/why-bluebird-bio-shares-dropped-today-2015-08-10", "https://www.nasdaq.com/articles/did-hillary-clinton-cause-bluebird-bio-slump-today-2015-09-21", "https://www.nasdaq.com/articles/rsi-alert-bluebird-bio-blue-now-oversold-2015-08-07", "https://www.nasdaq.com/articles/will-kite-pharma-kite-miss-earnings-estimates-yet-again-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/bluebird-bio-blue-sees-hammer-chart-pattern%3A-time-to-buy-tale-of-the-tape-2015-07-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/whats-bluebird-bios-pipeline-has-investors-so-excited-2015-07-19", "https://www.nasdaq.com/articles/why-shares-bluebird-bio-slumped-more-10-june-2015-07-08", "https://www.nasdaq.com/articles/kite-pharma-gains-after-striking-kte-c19-development-deal-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/why-bluebird-bio-falling-today-2015-08-07", "https://www.nasdaq.com/articles/bluebird-bio-reports-encouraging-data-on-thalassemia-drug-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/unique-case-small-cap-etfs-2015-06-16", "https://www.nasdaq.com/articles/stocks-watch-orphan-drugs-2015-06-09", "https://www.nasdaq.com/articles/health-care-sector-update-06092015-cbmgbluesageirwd-2015-06-09", "https://www.nasdaq.com/articles/3-surprising-biotech-stocks-are-surging-higher-2015-06-06", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwo-isis-dxcm-blue-2015-06-05", "https://www.nasdaq.com/articles/bluebird-amends-collaboration-agreement-with-celgene-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/kite-pharma-and-bluebird-tie-hpv-cancer-targets-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/investing-beginners-how-start-biotech-2015-05-30", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-jumps%3A-stock-rises-15.1-tale-of-the-tape-2015-05-28", "https://www.nasdaq.com/articles/futures-gain-traction-bargain-hunting-buoyed-tiffanys-earnings-2015-05-27", "https://www.nasdaq.com/articles/midday-update-stocks-recover-europe-swings-higher-investors-shop-bargains-2015-05-27", "https://www.nasdaq.com/articles/uh-oh-billionaire-george-soros-just-stepped-another-biotech-landmine-2015-05-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-eleven-biotherapeutics-bluebird-agios-acceleron-and", "https://www.nasdaq.com/articles/why-shares-bluebird-bio-inc-are-soaring-2015-05-21", "https://www.nasdaq.com/articles/bluebird-bio-larger-sp-500-component-allegion-plc-2015-06-03", "https://www.nasdaq.com/articles/bluebird-bio-plans-sing-june-2015-05-06", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-celladon-novavax-and-bluebird-bio-press", "https://www.nasdaq.com/articles/biotech-bubble-bursting-3-stocks-i-want-buy-2015-04-27", "https://www.nasdaq.com/articles/legalized-marijuana-or-gene-therapy-better-emerging-industry-2015-04-22", "https://www.nasdaq.com/articles/why-uniqure-nv-stock-skyrocketed-today-2015-04-06", "https://www.nasdaq.com/articles/3-events-could-sink-biotech-sector-year-2015-04-05", "https://www.nasdaq.com/articles/1-clinical-stage-biotech-stock-could-make-you-millionaire-2015-03-29", "https://www.nasdaq.com/articles/bluebird-bio-blue-shows-strength%3A-stock-rises-9.2-tale-of-the-tape-2015-05-08", "https://www.nasdaq.com/articles/use-options-chance-buy-blue-52-discount-2015-03-27", "https://www.nasdaq.com/articles/could-clinical-stage-biotech-stock-soar-april-2015-03-12", "https://www.nasdaq.com/articles/beware-sangamo-20-year-history-failures-misadventures-hiv-and-flawed-approach-b", "https://www.nasdaq.com/articles/use-options-chance-buy-blue-56-discount-2015-02-26", "https://www.nasdaq.com/articles/ecolabs-ecl-q4-earnings%3A-will-it-disappoint-estimates-analyst-blog-2015-02-20", "https://www.nasdaq.com/articles/will-labcorp-lh-surprise-earnings-estimates-this-season-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/will-dentsply-international-xray-miss-earnings-in-q4-analyst-blog-2015-02-16", "https://www.nasdaq.com/articles/could-these-experimental-drugs-eclipse-harvonis-historic-launch-2015-03-28", "https://www.nasdaq.com/articles/whats-in-store-for-acadia-healthcare-achc-this-earnings-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/bluebird-bios-thalassemia-drug-gets-breakthrough-status-analyst-blog-2015-02-05", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-jan-25-31-2015-2015-02-03", "https://www.nasdaq.com/articles/use-options-chance-buy-blue-31-discount-2015-01-28", "https://www.nasdaq.com/articles/5-cant-miss-reasons-why-celgene-corporation-could-soar-2015-01-26", "https://www.nasdaq.com/articles/state-union-address-investing-idea-precision-medicine-2015-01-21", "https://www.nasdaq.com/articles/first-week-blue-august-21st-options-trading-2015-01-14", "https://www.nasdaq.com/articles/will-masimo-corp-masi-disappoint-q4-earnings-estimates-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/3-clinical-stage-biotech-stocks-explosive-upside-potential-2015-2015-01-10", "https://www.nasdaq.com/articles/these-3-biotech-stocks-tripled-investors-money-2014-2015-01-04", "https://www.nasdaq.com/articles/growth-stocks-2015-3-companies-room-run-2015-01-04", "https://www.nasdaq.com/articles/how-these-3-stocks-doubled-investors-money-q4-2015-01-03", "https://www.nasdaq.com/articles/markets-top-10-stocks-2014-2015-01-03", "https://www.nasdaq.com/articles/insiders-were-right-bluebird-bio-makes-new-52-week-high-2014-12-30", "https://www.nasdaq.com/articles/use-options-chance-buy-bluebird-bio-34-discount-2014-12-30", "https://www.nasdaq.com/articles/celgene-corporation-takeover-target-2015-2015-01-12", "https://www.nasdaq.com/articles/3-clinical-stage-biotech-stocks-explosive-upside-potential-2015-2015-01-10", "https://www.nasdaq.com/articles/3-clinical-stage-biotech-stocks-should-be-your-watchlist-2015-2014-12-23", "https://www.nasdaq.com/articles/twitters-favorite-biotech-and-pharma-stocks-2014-12-16", "https://www.nasdaq.com/articles/bluebird-bio-blue-soars-on-data-from-lentiglobin-study-analyst-blog-2014-12-11", "https://www.nasdaq.com/articles/biotech-company-one-normal-risks-reduced-2014-12-09", "https://www.nasdaq.com/articles/us-stocks-seen-extending-losses-tune-world-markets-growth-concerns-weak-oil-futures-2014", "https://www.nasdaq.com/articles/bluebird-bio-blue-in-focus%3A-stock-surges-9.4-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xbi-agio-blue-rcpt-2014-12-24", "https://www.nasdaq.com/articles/use-options-chance-buy-bluebird-bio-39-discount-2014-11-25", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-bluebird-blue-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/will-quest-diagnostics-dgx-surprise-earnings-in-q3-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/will-zimmer-zmh-miss-earnings-estimates-this-quarter-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/will-boston-scientific-bsx-surprise-this-earnings-season-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/bluebird-bio-inc.-blue-in-focus%3A-stock-surges-10.24-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/bluebird-bio-director-buys-close-3000-shares-2014-07-15", "https://www.nasdaq.com/articles/us-futures-extend-losses-oil-prices-china-weigh-global-sentiment-2014-12-09", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-07-08", "https://www.nasdaq.com/articles/commit-buy-bluebird-bio-30-earn-442-annualized-using-options-2014-07-08", "https://www.nasdaq.com/articles/sector-update-healthcare-stocks-tumble-bluebird-bio-clipped-after-disclosing-plans-sell", "https://www.nasdaq.com/articles/fridays-etf-movers-ibb-gdxj-2014-06-20", "https://www.nasdaq.com/articles/bluebird-blue-enters-overbought-territory-tale-of-the-tape-2014-06-18", "https://www.nasdaq.com/articles/strength-seen-in-bluebird-bio-inc.-blue-as-stock-shoots-up-32.08-tale-of-the-tape-2014-06", "https://www.nasdaq.com/articles/sector-update-health-care-2014-07-09-0", "https://www.nasdaq.com/articles/bluebird-bio-blue-enters-overbought-territory-tale-of-the-tape-2014-05-20", "https://www.nasdaq.com/articles/bluebird-bio-blue-jumps%3A-stock-adds-27.3-in-session-tale-of-the-tape-2014-05-15", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-thursday-tale-of-the-tape-2014-04-10", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-04-07", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-wednesday-tale-of-the-tape-2014-03-12", "https://www.nasdaq.com/articles/bluebird-bio-blue-zooms%3A-stock-up-7.2-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/after-hours-most-active-feb-7-2014-bac-jnpr-ete-wmb-bhi-jpm-ttwo-qqq-wen-msft-blue-intc", "https://www.nasdaq.com/articles/pre-market-most-active-jun-16-2014-mdt-cov-fio-nok-wmb-blue-twtc-wft-yhoo-aaxj-achn-aapl", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-12-26-0", "https://www.nasdaq.com/articles/new-stock-coverage-time-put-your-nest-egg-twitter-2013-11-07", "https://www.nasdaq.com/articles/us-ipo-recap%3A-biotech-success-continues-but-three-deals-delayed-or-postponed-2013-06-24", "https://www.nasdaq.com/articles/bluebird-bio-prices-upsized-ipo-above-range-17-2013-06-18", "https://www.nasdaq.com/articles/6-us-ipos-planned-week-jun-17-2013-06-17", "https://www.nasdaq.com/articles/gene-therapy-biotech-bluebird-bio-sets-terms-75-million-ipo-2013-06-04", "https://www.nasdaq.com/articles/gene-therapy-biotech-bluebird-bio-files-86-million-ipo-2013-05-14", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-oramed-drops-16-share-offering-2013-12-26"], "Content": []}